EP3474900A1 - Dégradation de la protéine contenant un bromodomaine 9 (brd9) par conjugaison d'inhibiteurs de brd9 avec un ligand de la ligase e3 et procédés d'utilisation - Google Patents
Dégradation de la protéine contenant un bromodomaine 9 (brd9) par conjugaison d'inhibiteurs de brd9 avec un ligand de la ligase e3 et procédés d'utilisationInfo
- Publication number
- EP3474900A1 EP3474900A1 EP17816295.4A EP17816295A EP3474900A1 EP 3474900 A1 EP3474900 A1 EP 3474900A1 EP 17816295 A EP17816295 A EP 17816295A EP 3474900 A1 EP3474900 A1 EP 3474900A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- linker
- degron
- alkyl
- formula
- bifunctional compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102100029893 Bromodomain-containing protein 9 Human genes 0.000 title claims abstract description 176
- 101710126824 Bromodomain-containing protein 9 Proteins 0.000 title claims abstract description 176
- 238000000034 method Methods 0.000 title claims abstract description 96
- 239000003446 ligand Substances 0.000 title claims abstract description 85
- 230000015556 catabolic process Effects 0.000 title abstract description 38
- 238000006731 degradation reaction Methods 0.000 title abstract description 38
- 239000003112 inhibitor Substances 0.000 title description 54
- 230000021615 conjugation Effects 0.000 title description 7
- 102000003960 Ligases Human genes 0.000 title description 3
- 108090000364 Ligases Proteins 0.000 title description 3
- 101150052862 brd9 gene Proteins 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 405
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 169
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 130
- 150000003839 salts Chemical class 0.000 claims abstract description 82
- 230000027455 binding Effects 0.000 claims abstract description 30
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 20
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 124
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 114
- 206010028980 Neoplasm Diseases 0.000 claims description 96
- 201000010099 disease Diseases 0.000 claims description 83
- 230000008685 targeting Effects 0.000 claims description 72
- 201000011510 cancer Diseases 0.000 claims description 67
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 52
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 50
- 102000001805 Bromodomains Human genes 0.000 claims description 42
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 41
- 108050009021 Bromodomains Proteins 0.000 claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 17
- 206010025323 Lymphomas Diseases 0.000 claims description 16
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 206010017758 gastric cancer Diseases 0.000 claims description 11
- 208000032839 leukemia Diseases 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 201000010174 renal carcinoma Diseases 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 abstract description 71
- 239000000651 prodrug Substances 0.000 abstract description 71
- 238000011282 treatment Methods 0.000 abstract description 53
- 239000012453 solvate Substances 0.000 abstract description 48
- 208000035475 disorder Diseases 0.000 abstract description 46
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000017854 proteolysis Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 355
- 125000005647 linker group Chemical group 0.000 description 245
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 114
- 239000000203 mixture Substances 0.000 description 77
- 235000002639 sodium chloride Nutrition 0.000 description 77
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 73
- 108090000623 proteins and genes Proteins 0.000 description 64
- -1 n- propyl Chemical group 0.000 description 63
- 210000004027 cell Anatomy 0.000 description 62
- 102000004169 proteins and genes Human genes 0.000 description 61
- 235000018102 proteins Nutrition 0.000 description 52
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 41
- 230000000694 effects Effects 0.000 description 40
- 230000015572 biosynthetic process Effects 0.000 description 39
- 238000004020 luminiscence type Methods 0.000 description 35
- 239000002904 solvent Substances 0.000 description 30
- 230000003247 decreasing effect Effects 0.000 description 27
- 125000004429 atom Chemical group 0.000 description 26
- 229910052799 carbon Inorganic materials 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 25
- 239000002246 antineoplastic agent Substances 0.000 description 23
- 238000001262 western blot Methods 0.000 description 22
- 102000007469 Actins Human genes 0.000 description 21
- 108010085238 Actins Proteins 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 229940127089 cytotoxic agent Drugs 0.000 description 21
- 239000000126 substance Substances 0.000 description 20
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 description 18
- 102100032783 Protein cereblon Human genes 0.000 description 18
- 230000002062 proliferating effect Effects 0.000 description 18
- 230000001404 mediated effect Effects 0.000 description 16
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 229960003433 thalidomide Drugs 0.000 description 15
- 201000009030 Carcinoma Diseases 0.000 description 14
- 206010039491 Sarcoma Diseases 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229910001868 water Inorganic materials 0.000 description 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 13
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 230000000155 isotopic effect Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 108091005625 BRD4 Proteins 0.000 description 11
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 11
- 208000009956 adenocarcinoma Diseases 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000002552 dosage form Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000003491 skin Anatomy 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 208000034578 Multiple myelomas Diseases 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000003119 immunoblot Methods 0.000 description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 150000003384 small molecules Chemical class 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- WRUWGLUCNBMGPS-UHFFFAOYSA-N n'-(1,1-dioxothian-4-yl)-5-ethyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide Chemical compound C1=2SC(C(N)=NC3CCS(=O)(=O)CC3)=CC=2C(=O)N(CC)C=C1C1=CC=CC(C(F)(F)F)=C1 WRUWGLUCNBMGPS-UHFFFAOYSA-N 0.000 description 7
- 229940121655 pd-1 inhibitor Drugs 0.000 description 7
- 238000003419 tautomerization reaction Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- 102100029897 Bromodomain-containing protein 7 Human genes 0.000 description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 6
- 101000794019 Homo sapiens Bromodomain-containing protein 7 Proteins 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 239000012270 PD-1 inhibitor Substances 0.000 description 6
- 239000012668 PD-1-inhibitor Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 6
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 230000003389 potentiating effect Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000006663 ubiquitin-proteasome pathway Effects 0.000 description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 108010024976 Asparaginase Proteins 0.000 description 5
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 201000008808 Fibrosarcoma Diseases 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 5
- DNVXATUJJDPFDM-KRWDZBQOSA-N JQ1 Chemical compound N([C@@H](CC(=O)OC(C)(C)C)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 DNVXATUJJDPFDM-KRWDZBQOSA-N 0.000 description 5
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 229940125763 bromodomain inhibitor Drugs 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000004952 protein activity Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- INYSELGLAAADNH-UHFFFAOYSA-N 2-bromo-1,5,6,7-tetrahydropyrrolo[2,3-c]azepine-4,8-dione Chemical compound O=C1NCCC(=O)C2=C1NC(Br)=C2 INYSELGLAAADNH-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 description 4
- 239000012664 BCL-2-inhibitor Substances 0.000 description 4
- 229940124291 BTK inhibitor Drugs 0.000 description 4
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 4
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 4
- 108010002386 Interleukin-3 Proteins 0.000 description 4
- 102100039064 Interleukin-3 Human genes 0.000 description 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 4
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 4
- 102000017578 LAG3 Human genes 0.000 description 4
- 101150030213 Lag3 gene Proteins 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 4
- 206010043276 Teratoma Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000000973 chemotherapeutic effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000003701 inert diluent Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 206010027191 meningioma Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- CDOOFZZILLRUQH-GDLZYMKVSA-N n-[3-[6-[4-[(2r)-1,4-dimethyl-3-oxopiperazin-2-yl]anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)[C@H]1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-GDLZYMKVSA-N 0.000 description 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- KASDHRXLYQOAKZ-XDSKOBMDSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-XDSKOBMDSA-N 0.000 description 4
- 230000036515 potency Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229960002930 sirolimus Drugs 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical compound C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 description 3
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 3
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 3
- RMNLLPXCNDZJMJ-IDVLALEDSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 RMNLLPXCNDZJMJ-IDVLALEDSA-N 0.000 description 3
- NZNTWOVDIXCHHS-LSDHHAIUSA-N 2-{[(1r,2s)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide Chemical compound CC1=CC=CC(NC=2C(=CN=C(N[C@H]3[C@H](CCCC3)N)N=2)C(N)=O)=C1 NZNTWOVDIXCHHS-LSDHHAIUSA-N 0.000 description 3
- GNMUEVRJHCWKTO-FQEVSTJZSA-N 6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)- Chemical compound C([C@@H]1N=C(C2=C(N3C(C)=NN=C31)SC(=C2C)C)C=1C=CC(Cl)=CC=1)C(=O)NC1=CC=C(O)C=C1 GNMUEVRJHCWKTO-FQEVSTJZSA-N 0.000 description 3
- VUVUVNZRUGEAHB-CYBMUJFWSA-N 7-(3,5-dimethyl-4-isoxazolyl)-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-3H-imidazo[4,5-c]quinolin-2-one Chemical compound C1([C@@H](C)N2C3=C4C=C(C(=CC4=NC=C3NC2=O)C2=C(ON=C2C)C)OC)=CC=CC=N1 VUVUVNZRUGEAHB-CYBMUJFWSA-N 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 201000003076 Angiosarcoma Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102100020880 Kit ligand Human genes 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 description 3
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 229940124647 MEK inhibitor Drugs 0.000 description 3
- 208000000172 Medulloblastoma Diseases 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 201000010208 Seminoma Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 208000008383 Wilms tumor Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000011374 additional therapy Methods 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 229960000684 cytarabine Drugs 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 229960002448 dasatinib Drugs 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000003463 hyperproliferative effect Effects 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 230000008629 immune suppression Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 229960004942 lenalidomide Drugs 0.000 description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 3
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
- 229960003881 letrozole Drugs 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 229940124302 mTOR inhibitor Drugs 0.000 description 3
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 230000009527 neddylation Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229960001972 panitumumab Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Polymers 0.000 description 3
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical class O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 229940121649 protein inhibitor Drugs 0.000 description 3
- 239000012268 protein inhibitor Substances 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 229960001302 ridaforolimus Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 108010038379 sargramostim Proteins 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
- 201000002510 thyroid cancer Diseases 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 3
- 229960001183 venetoclax Drugs 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 3
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 2
- SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 2
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 2
- QDITZBLZQQZVEE-YBEGLDIGSA-N (5z)-5-[(4-pyridin-4-ylquinolin-6-yl)methylidene]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)\C1=C\C1=CC=C(N=CC=C2C=3C=CN=CC=3)C2=C1 QDITZBLZQQZVEE-YBEGLDIGSA-N 0.000 description 2
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- VFEYUQKREJGJHW-UHFFFAOYSA-N 2-(3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl)acetamide Chemical compound S1C=CC=2C=NC(C=3N(C=21)C=NN=3)CC(=O)N VFEYUQKREJGJHW-UHFFFAOYSA-N 0.000 description 2
- IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 2
- AAAQFGUYHFJNHI-SFHVURJKSA-N 2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide Chemical compound N([C@H](C1=NN=C(C)N1C1=CC=C(OC)C=C11)CC(=O)NCC)=C1C1=CC=C(Cl)C=C1 AAAQFGUYHFJNHI-SFHVURJKSA-N 0.000 description 2
- ZVWIXIGBWIEDFO-UHFFFAOYSA-N 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetic acid Chemical compound O=C1C=2C(OCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O ZVWIXIGBWIEDFO-UHFFFAOYSA-N 0.000 description 2
- WXJLXRNWMLWVFB-UHFFFAOYSA-N 2-chloro-5-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)phenol Chemical compound C1=C(Cl)C(O)=CC(C2=C(NC(=N2)C=2C=CC=CC=2)C=2C=CN=CC=2)=C1 WXJLXRNWMLWVFB-UHFFFAOYSA-N 0.000 description 2
- XTKLTGBKIDQGQL-UHFFFAOYSA-N 2-methyl-1-[[2-methyl-3-(trifluoromethyl)phenyl]methyl]-6-morpholin-4-ylbenzimidazole-4-carboxylic acid Chemical compound CC1=NC2=C(C(O)=O)C=C(N3CCOCC3)C=C2N1CC1=CC=CC(C(F)(F)F)=C1C XTKLTGBKIDQGQL-UHFFFAOYSA-N 0.000 description 2
- BEUQXVWXFDOSAQ-UHFFFAOYSA-N 2-methyl-2-[4-[2-(5-methyl-2-propan-2-yl-1,2,4-triazol-3-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]pyrazol-1-yl]propanamide Chemical compound CC(C)N1N=C(C)N=C1C1=CN(CCOC=2C3=CC=C(C=2)C2=CN(N=C2)C(C)(C)C(N)=O)C3=N1 BEUQXVWXFDOSAQ-UHFFFAOYSA-N 0.000 description 2
- ZGBGPEDJXCYQPH-UHFFFAOYSA-N 3-(2-cyanopropan-2-yl)-N-[4-methyl-3-[(3-methyl-4-oxo-6-quinazolinyl)amino]phenyl]benzamide Chemical compound C1=C(NC=2C=C3C(=O)N(C)C=NC3=CC=2)C(C)=CC=C1NC(=O)C1=CC=CC(C(C)(C)C#N)=C1 ZGBGPEDJXCYQPH-UHFFFAOYSA-N 0.000 description 2
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 description 2
- JDQNYWYMNFRKNQ-UHFFFAOYSA-N 3-ethyl-4-methylpyridine Chemical compound CCC1=CN=CC=C1C JDQNYWYMNFRKNQ-UHFFFAOYSA-N 0.000 description 2
- BGLPECHZZQDNCD-UHFFFAOYSA-N 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C(C=C1)=CC=C1NC1=NC=C(C(N)=O)C(NC2CC2)=N1 BGLPECHZZQDNCD-UHFFFAOYSA-N 0.000 description 2
- VVLHQJDAUIPZFH-UHFFFAOYSA-N 4-[4-[[5-fluoro-4-[3-(prop-2-enoylamino)anilino]pyrimidin-2-yl]amino]phenoxy]-n-methylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC=3N=C(NC=4C=C(NC(=O)C=C)C=CC=4)C(F)=CN=3)=CC=2)=C1 VVLHQJDAUIPZFH-UHFFFAOYSA-N 0.000 description 2
- ZCCPLJOKGAACRT-UHFFFAOYSA-N 4-methyl-3-[[1-methyl-6-(3-pyridinyl)-4-pyrazolo[3,4-d]pyrimidinyl]amino]-N-[3-(trifluoromethyl)phenyl]benzamide Chemical compound CC1=CC=C(C(=O)NC=2C=C(C=CC=2)C(F)(F)F)C=C1NC(C=1C=NN(C)C=1N=1)=NC=1C1=CC=CN=C1 ZCCPLJOKGAACRT-UHFFFAOYSA-N 0.000 description 2
- JIFCFQDXHMUPGP-UHFFFAOYSA-N 4-tert-butyl-n-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide Chemical compound C1=CC=C(C=2N=C(NC=3C=CC(=CC=3)C(=O)N3CCOCC3)C(=O)N(C)C=2)C(C)=C1NC(=O)C1=CC=C(C(C)(C)C)C=C1 JIFCFQDXHMUPGP-UHFFFAOYSA-N 0.000 description 2
- XSMSNFMDVXXHGJ-UHFFFAOYSA-N 6-(1h-indazol-6-yl)-n-(4-morpholin-4-ylphenyl)imidazo[1,2-a]pyrazin-8-amine Chemical compound C1COCCN1C(C=C1)=CC=C1NC1=NC(C=2C=C3NN=CC3=CC=2)=CN2C1=NC=C2 XSMSNFMDVXXHGJ-UHFFFAOYSA-N 0.000 description 2
- XJZVCDVZCRLIKN-QWHCGFSZSA-N 6-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[(5,6-dimethylpyridin-2-yl)amino]pyridazine-3-carboxamide Chemical compound N1=C(C)C(C)=CC=C1NC1=CC(N[C@H]2[C@H](CCCC2)N)=NN=C1C(N)=O XJZVCDVZCRLIKN-QWHCGFSZSA-N 0.000 description 2
- ZTUJNJAKTLHBEX-UHFFFAOYSA-N 6-cyclopropyl-8-fluoro-2-[2-(hydroxymethyl)-3-[1-methyl-5-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]-6-oxopyridin-3-yl]phenyl]isoquinolin-1-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=CC(C=2C(=C(C=CC=2)N2C(C3=C(F)C=C(C=C3C=C2)C2CC2)=O)CO)=CN(C)C1=O ZTUJNJAKTLHBEX-UHFFFAOYSA-N 0.000 description 2
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RTRNJQOBEOISFQ-UHFFFAOYSA-N 9-(1-methyl-4-pyrazolyl)-1-[1-(1-oxoprop-2-enyl)-2,3-dihydroindol-6-yl]-2-benzo[h][1,6]naphthyridinone Chemical compound C1=NN(C)C=C1C1=CC=C(N=CC2=C3N(C=4C=C5N(C(=O)C=C)CCC5=CC=4)C(=O)C=C2)C3=C1 RTRNJQOBEOISFQ-UHFFFAOYSA-N 0.000 description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102100033640 Bromodomain-containing protein 1 Human genes 0.000 description 2
- 108091005575 Bromodomain-containing proteins Proteins 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 102000012698 DDB1 Human genes 0.000 description 2
- 102100026662 Delta and Notch-like epidermal growth factor-related receptor Human genes 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- 108010029961 Filgrastim Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010069236 Goserelin Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000871846 Homo sapiens Bromodomain-containing protein 1 Proteins 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 206010023347 Keratoacanthoma Diseases 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 2
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- PBBRWFOVCUAONR-UHFFFAOYSA-N PP2 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1C1=CC=C(Cl)C=C1 PBBRWFOVCUAONR-UHFFFAOYSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229940078123 Ras inhibitor Drugs 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- HJSSPYJVWLTYHG-UHFFFAOYSA-N XL765 Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(NC(=O)C=3C=C(OC)C(C)=CC=3)=CC=2)=C1 HJSSPYJVWLTYHG-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- IBXPAFBDJCXCDW-MHFPCNPESA-A [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].Cc1cn([C@H]2C[C@H](O)[C@@H](COP([S-])(=O)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3COP([O-])(=S)O[C@H]3C[C@@H](O[C@@H]3CO)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3cnc4c3nc(N)[nH]c4=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O IBXPAFBDJCXCDW-MHFPCNPESA-A 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229950000080 birabresib Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 206010006007 bone sarcoma Diseases 0.000 description 2
- 229940083476 bosulif Drugs 0.000 description 2
- 229960003736 bosutinib Drugs 0.000 description 2
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 2
- 229960002438 carfilzomib Drugs 0.000 description 2
- 108010021331 carfilzomib Proteins 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229940126523 co-drug Drugs 0.000 description 2
- 229960002271 cobimetinib Drugs 0.000 description 2
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 2
- 101150077768 ddb1 gene Proteins 0.000 description 2
- 239000001064 degrader Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 230000002074 deregulated effect Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- HSYBQXDGYCYSGA-UHFFFAOYSA-L disodium;[6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-3-oxopyrido[3,2-b][1,4]oxazin-4-yl]methyl phosphate Chemical compound [Na+].[Na+].COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP([O-])([O-])=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 HSYBQXDGYCYSGA-UHFFFAOYSA-L 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 108010002601 epoetin beta Proteins 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- GKDRMWXFWHEQQT-UHFFFAOYSA-N fostamatinib Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4N(COP(O)(O)=O)C(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 GKDRMWXFWHEQQT-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 229960001507 ibrutinib Drugs 0.000 description 2
- 229960003445 idelalisib Drugs 0.000 description 2
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 2
- 229960003151 mercaptamine Drugs 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- RDSACQWTXKSHJT-UHFFFAOYSA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide Chemical compound C1CC1(CC(O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-UHFFFAOYSA-N 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- 238000013546 non-drug therapy Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 229960005554 obatoclax mesylate Drugs 0.000 description 2
- 229960000435 oblimersen Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- CGBJSGAELGCMKE-UHFFFAOYSA-N omipalisib Chemical compound COC1=NC=C(C=2C=C3C(C=4C=NN=CC=4)=CC=NC3=CC=2)C=C1NS(=O)(=O)C1=CC=C(F)C=C1F CGBJSGAELGCMKE-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229950010632 perifosine Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960005330 pimecrolimus Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 108090000765 processed proteins & peptides Chemical group 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000004063 proteosomal degradation Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- 229960002530 sargramostim Drugs 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- BQAZCCVUZDIZDC-UHFFFAOYSA-N sorafenib n-oxide Chemical compound C1=[N+]([O-])C(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 BQAZCCVUZDIZDC-UHFFFAOYSA-N 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 229940068117 sprycel Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000005556 structure-activity relationship Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 2
- 229940069905 tasigna Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960000235 temsirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- CZUHROWWGMKXBH-UHFFFAOYSA-N tert-butyl 2,9-diaminononanoate Chemical compound CC(C)(C)OC(=O)C(N)CCCCCCCN CZUHROWWGMKXBH-UHFFFAOYSA-N 0.000 description 2
- XXKJVZKHWPVYMP-UHFFFAOYSA-N tert-butyl N-[8-[[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]amino]octyl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCCCCNC(OC(C)(C)C)=O)=O)=O XXKJVZKHWPVYMP-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 2
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 description 1
- KGWWHPZQLVVAPT-STTJLUEPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(\C=C\C=2C=CC=CC=2)=N1 KGWWHPZQLVVAPT-STTJLUEPSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- ZVAGBRFUYHSUHA-LZOXOEDVSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole;methanesulfonic acid Chemical compound CS(O)(=O)=O.COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C ZVAGBRFUYHSUHA-LZOXOEDVSA-N 0.000 description 1
- KCOYQXZDFIIGCY-CZIZESTLSA-N (3e)-4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one Chemical compound C1CN(C)CCN1C1=CC=C(N\C(N2)=C/3C(=C4C(F)=CC=CC4=NC\3=O)N)C2=C1 KCOYQXZDFIIGCY-CZIZESTLSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- OYYVWNDMOQPMGE-SDQBBNPISA-N (5z)-5-[[5-(4-fluoro-2-hydroxyphenyl)furan-2-yl]methylidene]-1,3-thiazolidine-2,4-dione Chemical compound OC1=CC(F)=CC=C1C(O1)=CC=C1\C=C/1C(=O)NC(=O)S\1 OYYVWNDMOQPMGE-SDQBBNPISA-N 0.000 description 1
- MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIELZHYJYZBSGG-UHFFFAOYSA-N 10-(3-aminopropyl)-3,4-dimethylacridin-9-one;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3N(CCCN)C2=C1 IIELZHYJYZBSGG-UHFFFAOYSA-N 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N 15-Deoxyspergualin Natural products NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- RWEVIPRMPFNTLO-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-3-pyridinecarboxamide Chemical compound CN1C(=O)C(C)=CC(C(=O)NOCCO)=C1NC1=CC=C(I)C=C1F RWEVIPRMPFNTLO-UHFFFAOYSA-N 0.000 description 1
- TXQPXJKRNHJWAX-UHFFFAOYSA-N 2-(3-aminopropylamino)ethylsulfanylphosphonic acid;trihydrate Chemical compound O.O.O.NCCCNCCSP(O)(O)=O TXQPXJKRNHJWAX-UHFFFAOYSA-N 0.000 description 1
- LXMGXMQQJNULPR-NTISSMGPSA-N 2-[(4S)-6-(4-chlorophenyl)-1-methyl-4H-[1,2]oxazolo[5,4-d][2]benzazepin-4-yl]acetamide hydrate Chemical compound O.Cc1noc2[C@H](CC(N)=O)N=C(c3ccc(Cl)cc3)c3ccccc3-c12 LXMGXMQQJNULPR-NTISSMGPSA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- MCIDWGZGWVSZMK-UHFFFAOYSA-N 2-[6-(1h-indol-4-yl)-1h-indazol-4-yl]-5-[(4-propan-2-ylpiperazin-1-yl)methyl]-1,3-oxazole Chemical compound C1CN(C(C)C)CCN1CC1=CN=C(C=2C=3C=NNC=3C=C(C=2)C=2C=3C=CNC=3C=CC=2)O1 MCIDWGZGWVSZMK-UHFFFAOYSA-N 0.000 description 1
- IRTDIKMSKMREGO-OAHLLOKOSA-N 2-[[(1R)-1-[7-methyl-2-(4-morpholinyl)-4-oxo-9-pyrido[1,2-a]pyrimidinyl]ethyl]amino]benzoic acid Chemical compound N([C@H](C)C=1C=2N(C(C=C(N=2)N2CCOCC2)=O)C=C(C)C=1)C1=CC=CC=C1C(O)=O IRTDIKMSKMREGO-OAHLLOKOSA-N 0.000 description 1
- TXGKRVFSSHPBAJ-JKSUJKDBSA-N 2-[[(1r,2s)-2-aminocyclohexyl]amino]-4-[3-(triazol-2-yl)anilino]pyrimidine-5-carboxamide Chemical compound N[C@H]1CCCC[C@H]1NC1=NC=C(C(N)=O)C(NC=2C=C(C=CC=2)N2N=CC=N2)=N1 TXGKRVFSSHPBAJ-JKSUJKDBSA-N 0.000 description 1
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- KBPYMFSSFLOJPH-UONOGXRCSA-N 2-[[(3r,4r)-3-aminooxan-4-yl]amino]-4-(4-methylanilino)pyrimidine-5-carboxamide Chemical compound C1=CC(C)=CC=C1NC1=NC(N[C@H]2[C@H](COCC2)N)=NC=C1C(N)=O KBPYMFSSFLOJPH-UONOGXRCSA-N 0.000 description 1
- JWQOJVOKBAAAAR-UHFFFAOYSA-N 2-[[7-(3,4-dimethoxyphenyl)-5-imidazo[1,2-c]pyrimidinyl]amino]-3-pyridinecarboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN2C(NC=2C(=CC=CN=2)C(N)=O)=N1 JWQOJVOKBAAAAR-UHFFFAOYSA-N 0.000 description 1
- HLYFDKZWVIBYKL-UHFFFAOYSA-N 2-[[7-(3,4-dimethoxyphenyl)imidazo[1,2-c]pyrimidin-5-yl]amino]pyridine-3-carboxamide;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1C1=CC2=NC=CN2C(NC=2C(=CC=CN=2)C(N)=O)=N1 HLYFDKZWVIBYKL-UHFFFAOYSA-N 0.000 description 1
- SXJDCULZDFWMJC-UHFFFAOYSA-N 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-1-benzopyran-3-carboxylic acid ethyl ester Chemical compound C1=C(Br)C=C2C(C(C#N)C(=O)OCC)C(C(=O)OCC)=C(N)OC2=C1 SXJDCULZDFWMJC-UHFFFAOYSA-N 0.000 description 1
- RGHYDLZMTYDBDT-UHFFFAOYSA-N 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone Chemical compound O=C1N(CC)C2=NC(N)=NC(C)=C2C=C1C=1C=CNN=1 RGHYDLZMTYDBDT-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HTSNMAQKHKWFBA-UHFFFAOYSA-N 2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one Chemical compound N=1NC(N2C=1C=1C=CC=NC=1C=C2)=O HTSNMAQKHKWFBA-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- TVKGTSHBQZEFEE-UHFFFAOYSA-N 3-[[5-fluoro-2-(3-hydroxyanilino)pyrimidin-4-yl]amino]phenol Chemical compound OC1=CC=CC(NC=2N=C(NC=3C=C(O)C=CC=3)C(F)=CN=2)=C1 TVKGTSHBQZEFEE-UHFFFAOYSA-N 0.000 description 1
- YCPULGHBTPQLRH-UHFFFAOYSA-N 3-aminopiperidine-2,6-dione;hydron;chloride Chemical compound Cl.NC1CCC(=O)NC1=O YCPULGHBTPQLRH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- PXSGRWNXASCGTJ-UHFFFAOYSA-N 3-methyl-5-propan-2-yl-2-(1,4,6,7-tetrahydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,4,6,7-tetrone Chemical compound CC(C)c1c(O)c(O)cc2c(O)c(c(C)c(O)c12)-c1c(C)c(=O)c2c(C(C)C)c(=O)c(=O)cc2c1=O PXSGRWNXASCGTJ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 1
- JDUBGYFRJFOXQC-KRWDZBQOSA-N 4-amino-n-[(1s)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide Chemical compound C1([C@H](CCO)NC(=O)C2(CCN(CC2)C=2C=3C=CNC=3N=CN=2)N)=CC=C(Cl)C=C1 JDUBGYFRJFOXQC-KRWDZBQOSA-N 0.000 description 1
- HHZIURLSWUIHRB-BMSJAHLVSA-N 4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-n-[3-[4-(trideuteriomethyl)imidazol-1-yl]-5-(trifluoromethyl)phenyl]benzamide Chemical compound C1=NC(C([2H])([2H])[2H])=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-BMSJAHLVSA-N 0.000 description 1
- NHHQJBCNYHBUSI-UHFFFAOYSA-N 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(NC=3N=C4NC(=O)C(C)(C)OC4=CC=3)C(F)=CN=2)=C1 NHHQJBCNYHBUSI-UHFFFAOYSA-N 0.000 description 1
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical compound C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- BSSBAJKNZOHHCA-UHFFFAOYSA-N 7-benzyl-1-(3-piperidin-1-ylpropyl)-2-(4-pyridin-4-ylphenyl)-5h-imidazo[4,5-g]quinoxalin-6-one Chemical compound C1CCCCN1CCCN1C=2C=C3N=C(CC=4C=CC=CC=4)C(=O)NC3=CC=2N=C1C(C=C1)=CC=C1C1=CC=NC=C1 BSSBAJKNZOHHCA-UHFFFAOYSA-N 0.000 description 1
- YEAHTLOYHVWAKW-UHFFFAOYSA-N 8-(1-hydroxyethyl)-2-methoxy-3-[(4-methoxyphenyl)methoxy]benzo[c]chromen-6-one Chemical compound C1=CC(OC)=CC=C1COC(C(=C1)OC)=CC2=C1C1=CC=C(C(C)O)C=C1C(=O)O2 YEAHTLOYHVWAKW-UHFFFAOYSA-N 0.000 description 1
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- CPRAGQJXBLMUEL-UHFFFAOYSA-N 9-(1-anilinoethyl)-7-methyl-2-(4-morpholinyl)-4-pyrido[1,2-a]pyrimidinone Chemical compound C=1C(C)=CN(C(C=C(N=2)N3CCOCC3)=O)C=2C=1C(C)NC1=CC=CC=C1 CPRAGQJXBLMUEL-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 1
- 229960005531 AMG 319 Drugs 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 206010006417 Bronchial carcinoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- LMMJFBMMJUMSJS-UHFFFAOYSA-N CH5126766 Chemical compound CNS(=O)(=O)NC1=NC=CC(CC=2C(OC3=CC(OC=4N=CC=CN=4)=CC=C3C=2C)=O)=C1F LMMJFBMMJUMSJS-UHFFFAOYSA-N 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- HFOBENSCBRZVSP-LKXGYXEUSA-N C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O Chemical compound C[C@@H](O)[C@H](NC(=O)N[C@@H](CC(N)=O)c1nc(no1)[C@@H](N)CO)C(O)=O HFOBENSCBRZVSP-LKXGYXEUSA-N 0.000 description 1
- 101100533762 Caenorhabditis elegans snf-5 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000036364 Cullin Ring E3 Ligases Human genes 0.000 description 1
- 108091007045 Cullin Ring E3 Ligases Proteins 0.000 description 1
- 101710094481 Cullin-4 Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- ZINBFGBAIFRYSH-UHFFFAOYSA-N Demethoxyviridin Natural products CC12C(O)C(O)C(=O)c3coc(C(=O)c4c5CCC(=O)c5ccc14)c23 ZINBFGBAIFRYSH-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010073153 Familial medullary thyroid cancer Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000031995 Gorlin syndrome Diseases 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- QYZRTBKYBJRGJB-PCMHIUKPSA-N Granisetron hydrochloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-PCMHIUKPSA-N 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101000794032 Homo sapiens Bromodomain-containing protein 9 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 description 1
- 239000002137 L01XE24 - Ponatinib Substances 0.000 description 1
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
- 229940125563 LAG3 inhibitor Drugs 0.000 description 1
- UVSVTDVJQAJIFG-VURMDHGXSA-N LFM-A13 Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC(Br)=CC=C1Br UVSVTDVJQAJIFG-VURMDHGXSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 229940125568 MGD013 Drugs 0.000 description 1
- 229940124640 MK-2206 Drugs 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 1
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 1
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 1
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 1
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028561 Myeloid metaplasia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- FOFDIMHVKGYHRU-UHFFFAOYSA-N N-(1,3-benzodioxol-5-ylmethyl)-4-(4-benzofuro[3,2-d]pyrimidinyl)-1-piperazinecarbothioamide Chemical compound C12=CC=CC=C2OC2=C1N=CN=C2N(CC1)CCN1C(=S)NCC1=CC=C(OCO2)C2=C1 FOFDIMHVKGYHRU-UHFFFAOYSA-N 0.000 description 1
- AJVLNIUPDHKOPS-UHFFFAOYSA-N N-(8-aminooctyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide 2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NCCCCCCCCNC(=O)COc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 AJVLNIUPDHKOPS-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- VRSLTNZJOUZKLX-UHFFFAOYSA-N Ondansetron hydrochloride Chemical compound O.O.Cl.CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 VRSLTNZJOUZKLX-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 description 1
- 239000012272 PD-L2 inhibitor Substances 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010016672 Syk Kinase Proteins 0.000 description 1
- 201000008736 Systemic mastocytosis Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000009171 T-cell vaccination Methods 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- HGVNLRPZOWWDKD-UHFFFAOYSA-N ZSTK-474 Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CCOCC2)=NC=1N1CCOCC1 HGVNLRPZOWWDKD-UHFFFAOYSA-N 0.000 description 1
- OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- CFASDUOKNNDYAT-PFQKEVSBSA-N [(2r,3s,6s,7r,8r)-8-butyl-3-[(3-formamido-2-methoxybenzoyl)amino]-2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl] 3-methylbutanoate Chemical compound C[C@H]1OC(=O)[C@H](CCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1OC CFASDUOKNNDYAT-PFQKEVSBSA-N 0.000 description 1
- LVBMFPUTQOHXQE-UHFFFAOYSA-N [2-[6-(diaminomethylideneamino)hexylamino]-2-oxoethyl] n-[4-(3-aminopropylamino)butyl]carbamate Chemical compound NCCCNCCCCNC(=O)OCC(=O)NCCCCCCN=C(N)N LVBMFPUTQOHXQE-UHFFFAOYSA-N 0.000 description 1
- YYLKKYCXAOBSRM-JXMROGBWSA-N [4-[(e)-2-(1h-indazol-3-yl)ethenyl]phenyl]-piperazin-1-ylmethanone Chemical compound C=1C=C(\C=C\C=2C3=CC=CC=C3NN=2)C=CC=1C(=O)N1CCNCC1 YYLKKYCXAOBSRM-JXMROGBWSA-N 0.000 description 1
- 229960003697 abatacept Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 230000011759 adipose tissue development Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940042992 afinitor Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960002459 alefacept Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960003235 allopurinol sodium Drugs 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940127079 antineoplastic immunimodulatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- OVDSPTSBIQCAIN-UHFFFAOYSA-N ap26113 Chemical compound COC1=CC(N2CCC(CC2)N(C)C)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O OVDSPTSBIQCAIN-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229940059756 arava Drugs 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072224 asacol Drugs 0.000 description 1
- ZDQSOHOQTUFQEM-PKUCKEGBSA-N ascomycin Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C\C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](O)[C@H](OC)C1 ZDQSOHOQTUFQEM-PKUCKEGBSA-N 0.000 description 1
- ZDQSOHOQTUFQEM-XCXYXIJFSA-N ascomycin Natural products CC[C@H]1C=C(C)C[C@@H](C)C[C@@H](OC)[C@H]2O[C@@](O)([C@@H](C)C[C@H]2OC)C(=O)C(=O)N3CCCC[C@@H]3C(=O)O[C@H]([C@H](C)[C@@H](O)CC1=O)C(=C[C@@H]4CC[C@@H](O)[C@H](C4)OC)C ZDQSOHOQTUFQEM-XCXYXIJFSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229940092117 atgam Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229960005347 belatacept Drugs 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 1
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 208000019664 bone resorption disease Diseases 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 229950004272 brigatinib Drugs 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960001292 cabozantinib Drugs 0.000 description 1
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229940056434 caprelsa Drugs 0.000 description 1
- 150000001715 carbamic acids Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229940107810 cellcept Drugs 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229950006295 cerdulatinib Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960001602 ceritinib Drugs 0.000 description 1
- WRXDGGCKOUEOPW-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)NS(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 WRXDGGCKOUEOPW-UHFFFAOYSA-N 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- OHNBIIZWIUBGTK-NYPSMHOZSA-N cid_23581792 Chemical compound O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 OHNBIIZWIUBGTK-NYPSMHOZSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000000562 conjugate Substances 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- QECMENZMDBOLDR-AWEZNQCLSA-N cpi 203 Chemical compound N([C@@H](CC(N)=O)C1=NN=C(N1C=1SC(C)=C(C)C=11)C)=C1C1=CC=C(Cl)C=C1 QECMENZMDBOLDR-AWEZNQCLSA-N 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 102000022604 damaged DNA binding proteins Human genes 0.000 description 1
- 108091013406 damaged DNA binding proteins Proteins 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229940026692 decadron Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- SWJBYJJNDIXFSA-KUHUBIRLSA-N demethoxyviridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@]2(C)C3=C1OC=C3C(=O)C[C@H]2O SWJBYJJNDIXFSA-KUHUBIRLSA-N 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003218 dolasetron mesylate Drugs 0.000 description 1
- 229950005778 dovitinib Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 229960000284 efalizumab Drugs 0.000 description 1
- 229940056913 eftilagimod alfa Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 229940020485 elidel Drugs 0.000 description 1
- 229940073038 elspar Drugs 0.000 description 1
- XDXWLKQMMKQXPV-QYQHSDTDSA-N eltrombopag Chemical compound CC1=NN(C=2C=C(C)C(C)=CC=2)C(=O)\C1=N/NC(C=1O)=CC=CC=1C1=CC=CC(C(O)=O)=C1 XDXWLKQMMKQXPV-QYQHSDTDSA-N 0.000 description 1
- 229960001069 eltrombopag Drugs 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 229950004136 entospletinib Drugs 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 108010067416 epoetin delta Proteins 0.000 description 1
- 229950002109 epoetin delta Drugs 0.000 description 1
- 108010090921 epoetin omega Proteins 0.000 description 1
- 229950008767 epoetin omega Drugs 0.000 description 1
- 108010030868 epoetin zeta Proteins 0.000 description 1
- 229950005185 epoetin zeta Drugs 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 235000011990 fisetin Nutrition 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 229950005309 fostamatinib Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229950004792 gavilimomab Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229940121569 ieramilimab Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical compound C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940124622 immune-modulator drug Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940074383 interleukin-11 Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960002293 leucovorin calcium Drugs 0.000 description 1
- 229940087875 leukine Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940034322 marqibo Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229960005558 mertansine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- SULMJWJPVDSFFN-SNVBAGLBSA-N methyl-oxo-[(2r)-1-phenoxybutan-2-yl]oxyphosphanium Chemical compound C[P+](=O)O[C@H](CC)COC1=CC=CC=C1 SULMJWJPVDSFFN-SNVBAGLBSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- UCISVEKCUIGBJX-UHFFFAOYSA-N n'-(1,1-dioxothian-4-yl)-5-methyl-4-oxo-7-[3-(trifluoromethyl)phenyl]thieno[3,2-c]pyridine-2-carboximidamide Chemical compound C1=2SC(C(N)=NC3CCS(=O)(=O)CC3)=CC=2C(=O)N(C)C=C1C1=CC=CC(C(F)(F)F)=C1 UCISVEKCUIGBJX-UHFFFAOYSA-N 0.000 description 1
- KWRYMZHCQIOOEB-LBPRGKRZSA-N n-[(1s)-1-(7-fluoro-2-pyridin-2-ylquinolin-3-yl)ethyl]-7h-purin-6-amine Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=C(F)C=C2N=C1C1=CC=CC=N1 KWRYMZHCQIOOEB-LBPRGKRZSA-N 0.000 description 1
- BLUYEPLOXLPVCJ-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxyethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC[C@H](O)NC(=O)CCCCCCNC(N)=N BLUYEPLOXLPVCJ-INIZCTEOSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- CDOOFZZILLRUQH-UHFFFAOYSA-N n-[3-[6-[4-(1,4-dimethyl-3-oxopiperazin-2-yl)anilino]-4-methyl-5-oxopyrazin-2-yl]-2-methylphenyl]-4,5,6,7-tetrahydro-1-benzothiophene-2-carboxamide Chemical compound CN1CCN(C)C(=O)C1C(C=C1)=CC=C1NC1=NC(C=2C(=C(NC(=O)C=3SC=4CCCCC=4C=3)C=CC=2)C)=CN(C)C1=O CDOOFZZILLRUQH-UHFFFAOYSA-N 0.000 description 1
- KEDAVYHDQWPBEY-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methoxy-4-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=C(OC)C(C)=CC=3)C=CC=2)=C1 KEDAVYHDQWPBEY-UHFFFAOYSA-N 0.000 description 1
- KXBDTLQSDKGAEB-UHFFFAOYSA-N n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 KXBDTLQSDKGAEB-UHFFFAOYSA-N 0.000 description 1
- GDCJHDUWWAKBIW-UHFFFAOYSA-N n-[4-[4-[2-(difluoromethyl)-4-methoxybenzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]phenyl]-2-(dimethylamino)ethanesulfonamide Chemical compound FC(F)C1=NC=2C(OC)=CC=CC=2N1C(N=1)=NC(N2CCOCC2)=NC=1C1=CC=C(NS(=O)(=O)CCN(C)C)C=C1 GDCJHDUWWAKBIW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- JOWXJLIFIIOYMS-UHFFFAOYSA-N n-hydroxy-2-[[2-(6-methoxypyridin-3-yl)-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl-methylamino]pyrimidine-5-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=NC(N2CCOCC2)=C(SC(CN(C)C=2N=CC(=CN=2)C(=O)NO)=C2)C2=N1 JOWXJLIFIIOYMS-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 229940063121 neoral Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229940071846 neulasta Drugs 0.000 description 1
- 229940029345 neupogen Drugs 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001494 octreotide acetate Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940099216 oncaspar Drugs 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 229940029358 orthoclone okt3 Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229940096763 panretin Drugs 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940112824 paste Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 229940121654 pd-l2 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960005547 pelareorep Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 229950004941 pictilisib Drugs 0.000 description 1
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 description 1
- 229950002592 pimasertib Drugs 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 201000002511 pituitary cancer Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229940098901 polifeprosan 20 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229960001131 ponatinib Drugs 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N poseltinib Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(OC=C2)C2=N1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 description 1
- 229930192524 radicicol Natural products 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 229950008933 refametinib Drugs 0.000 description 1
- 229960004836 regorafenib Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 108010017584 romiplostim Proteins 0.000 description 1
- 229960004262 romiplostim Drugs 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- BLGWHBSBBJNKJO-UHFFFAOYSA-N serabelisib Chemical compound C=1C=C2OC(N)=NC2=CC=1C(=CN12)C=CC1=NC=C2C(=O)N1CCOCC1 BLGWHBSBBJNKJO-UHFFFAOYSA-N 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 229950003804 siplizumab Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 101150065181 snf-5 gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PTJRZVJXXNYNLN-UHFFFAOYSA-M sodium;2h-pyrazolo[3,4-d]pyrimidin-1-id-4-one Chemical compound [Na+].[O-]C1=NC=NC2=C1C=NN2 PTJRZVJXXNYNLN-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 229950007865 sonolisib Drugs 0.000 description 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
- 229960000487 sorafenib tosylate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229950007213 spartalizumab Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 229940090374 stivarga Drugs 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- MPUQHZXIXSTTDU-QXGSTGNESA-N sulfamic acid [(1S,2S,4R)-4-[4-[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]-7-pyrrolo[2,3-d]pyrimidinyl]-2-hydroxycyclopentyl]methyl ester Chemical compound C1[C@H](O)[C@H](COS(=O)(=O)N)C[C@H]1N1C2=NC=NC(N[C@@H]3C4=CC=CC=C4CC3)=C2C=C1 MPUQHZXIXSTTDU-QXGSTGNESA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 1
- 229940127072 targeted antineoplastic agent Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950001269 taselisib Drugs 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N tcn-p Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- SBNNKCCXJSOWRV-UHFFFAOYSA-N tert-butyl 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)OC(C)(C)C)=O)=O SBNNKCCXJSOWRV-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- VKXAKOZLIDXWGR-UHFFFAOYSA-N tert-butyl 4-[1-[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetyl]piperidin-4-yl]piperidine-1-carboxylate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)N1CCC(CC1)C1CCN(CC1)C(=O)OC(C)(C)C)=O)=O VKXAKOZLIDXWGR-UHFFFAOYSA-N 0.000 description 1
- NERBLCVCQKXTEP-UHFFFAOYSA-N tert-butyl 4-piperidin-4-ylpiperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1CCNCC1 NERBLCVCQKXTEP-UHFFFAOYSA-N 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229940107955 thymoglobulin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 208000025358 tongue carcinoma Diseases 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960004167 toremifene citrate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001612 trastuzumab emtansine Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229950007229 tresperimus Drugs 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- QTFFGPOXNNGTGZ-RCSCTSIBSA-N u3c8e5bwkr Chemical compound O.CS(O)(=O)=O.C1=CC=C2C(C(OC3C[C@@H]4CC5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 QTFFGPOXNNGTGZ-RCSCTSIBSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- 229960002110 vincristine sulfate Drugs 0.000 description 1
- 229960002166 vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 229940069559 votrient Drugs 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 description 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- 229940036061 zaltrap Drugs 0.000 description 1
- 229940034727 zelboraf Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 229960002760 ziv-aflibercept Drugs 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/556—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells enzyme catalyzed therapeutic agent [ECTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- UPP Ubiquitin-Proteasome Pathway
- E3 ubiquitin ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity. For example, cereblon (CRBN) interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 in which the proteins recognized by CRBN are ubiquitinated and degraded by proteasomes.
- immunomodulatory drugs e.g., thalidomide and lenalidomide
- CRBN CRBN
- thalidomide and lenalidomide binds to CRBN and modulates CRBN’s role in the ubiquitination and degradation of protein factors involved in maintaining regular cellular function.
- Bifunctional compounds composed of a target protein-binding moiety and an E3 ubiquitin ligase-binding moiety have been shown to induce proteasome-mediated degradation of selected proteins. These drug-like molecules offer the possibility of temporal control over protein expression, and could be useful as biochemical reagents for the treatment of diseases.
- SWI/SNF or BAF nucleosome-remodeling complex is part of the SWI/SNF or BAF nucleosome-remodeling complex.
- the SWI/SNF or BAF nucleosome-remodeling complex is a highly conserved multi-subunit complex, which uses the energy of ATP hydrolysis to remodel chromatin and mobilize nucleosomes.
- SWI/SNF has also been shown to be required for transcriptional repression of some genes, suggesting that SWI/SNF controls transcription in diverse ways.
- SWI/SNF possess intrinsic tumour-suppressor activity or are required for the activity of other tumour-suppressor genes, supporting a role of this complex in cancer development.
- conditional inactivation of the Snf5 gene results in a highly penetrant cancer phenotype in mice.
- genes encoding subunits of the SWI/SNF or BAF complex are mutated in cancer about 20% of the time.
- the present application relates to novel bifunctional compounds, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
- the bifunctional com ound is of Formula X:
- Targeting Ligand is capable of binding to a targeted protein, such as a
- bromodomain-containing protein e.g., BRD9
- the Linker is a group that covalently binds to the Targeting Ligand and the Degron;
- the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon).
- a ubiquitin ligase such as an E3 ubiquitin ligase (e.g., cereblon).
- the present application also relates to targeted degradation of proteins through the use of bifunctional compounds, including bifunctional compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds the targeted proteins.
- bifunctional compounds including bifunctional compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds the targeted proteins.
- R 1 , R 2 , A, and n are each as defined herein;
- the Linker is a group that covalently binds to in Formula (I) and the Degron;
- the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (i.e., cereblon); and
- Targeting Ligand is capable of binding to a targeted protein, such as BRD9.
- the present application further relates to a Degron of Formula D1 or Formula D2:
- Y, Z, Z 4 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , v, q, and q' are each as defined herein.
- the present application further includes a Linker of Formula L1, L2, or L3:
- the Linker is covalently bonded to a Degron via the next to Q, Q 2 , or Q 3 , and covalently bonded to a Targeting Ligand via the next to
- the present application also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier.
- Another aspect of the present application relates to a method of inhibiting a bromodomain protein (e.g., BRD9).
- the method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- Another aspect of the present application relates to a method of modulating (e.g., decreasing) the amount of a bromodomain protein (e.g., BRD9).
- the method comprises administering to a subject in need thereof a therapeutically effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- Another aspect of the present application relates to a method of inhibiting BRD9.
- the method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- Another aspect of the present application relates to a method of modulating BRD9.
- the method comprises administering to a subject in need thereof a therapeutically effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- Another aspect of the present application relates to a method of treating or preventing a disease (e.g., a disease in which BRD9 plays a role).
- the method comprises administering to a subject in need thereof an effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- the disease is BRD9 mediated disorder.
- the disease is a proliferative disease (e.g., a proliferative disease in which BRD9 plays a role).
- Another aspect of the present application relates to a method of treating or preventing cancer in a subject, wherein the cancer cell comprises an activated BRD9 or wherein the subject is identified as being in need of BRD9 inhibition for the treatment or prevention of cancer.
- the method comprises administering to the subject an effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application.
- kits comprising a bifunctional compound capable of inhibiting BRD9 activity, selected from a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof.
- kits comprising a bifunctional compound capable of modulating (e.g., decreasing) the amount of BRD9, selected from a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof.
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for inhibiting a bromodomain protein (e.g., BRD9) or for modulating (e.g., decreasing) the amount of a bromodomain protein (e.g., BRD9).
- a bromodomain protein e.g., BRD9
- BRD9 bromodomain protein
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for inhibiting BRD9 or for modulating (e.g., decreasing) the amount of BRD9.
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for treating or preventing a disease (e.g., a disease in which BRD9 plays a role).
- a disease e.g., a disease in which BRD9 plays a role
- the disease is a BRD9 mediated disorder.
- the disease is a proliferative disease (e.g., a proliferative disease in which BRD9 plays a role).
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in the manufacture of a medicament for treating or preventing cancer in a subject, wherein the cancer cell comprises an activated BRD9 or wherein the subject is identified as being in need of BRD9 inhibition for the treatment or prevention of cancer.
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in inhibiting a bromodomain protein (e.g., BRD9) or modulating (e.g., decreasing) the amount of a bromodomain protein (e.g., BRD9).
- a bromodomain protein e.g., BRD9
- modulating e.g., decreasing
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in inhibiting BRD9 or modulating (e.g., decreasing) the amount of BRD9.
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in treating or preventing a disease (e.g., a disease in which BRD9 plays a role).
- a disease e.g., a disease in which BRD9 plays a role
- the disease is BRD9 mediated disorder.
- the disease is a proliferative disease (e.g., a proliferative disease in which BRD9 plays a role).
- Another aspect of the present application relates to a bifunctional compound of the application, or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, or a pharmaceutical composition of the application, for use in treating or preventing cancer in a subject, wherein the cancer cell comprises an activated BRD9 or wherein the subject is identified as being in need of BRD9 inhibition for the treatment or prevention of cancer.
- the present application provides inhibitors of BRD9 that are therapeutic agents in the treatment or prevention of diseases such as cancer and metastasis.
- the present application further provides compounds and compositions with an improved efficacy and/or safety profile relative to known BRD9 inhibitors.
- the present application also provides agents with novel mechanisms of action toward BRD9 proteins in the treatment of various types of diseases including cancer and metastasis.
- the compounds and methods of the present application address unmet needs in the treatment of diseases or disorders in which pathogenic or oncogenic endogenous proteins (e.g., BRD9) play a role, such as cancer.
- pathogenic or oncogenic endogenous proteins e.g., BRD9
- FIG.1A is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-1 and unmodified thalidomide as detected by luminescence. The luminescence signal was measured as the concentration of compound I-1 and
- thalidomide was decreased.
- Compound I-1 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.1B is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-2 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-2 and
- thalidomide was decreased.
- Compound I-2 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.1C is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-3 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-3 and thalidomide was decreased.
- Compound I-3 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.2A is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-8 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-8 and thalidomide was decreased.
- Compound I-8 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.2B is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-7 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-7 and thalidomide was decreased.
- Compound I-7 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.2C is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-9 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-9 and thalidomide was decreased.
- Compound I-9 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.3A is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-5 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I-5 and thalidomide was decreased.
- Compound I-5 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.3B is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-17 and un ied thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I- 17 and thalidomide was decreased.
- Compound I-17 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.3C is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-12 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I- 12 and thalidomide was decreased.
- Compound I-12 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.4A is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-15 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I- 15 and thalidomide was decreased.
- Compound I-15 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.4B is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-24 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I- 24 and thalidomide was decreased.
- Compound I-24 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.4C is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compound I-25 and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of compound I- 25 and thalidomide was decreased.
- Compound I-25 was able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.5A is a Western Blot image of the effect of 500, 50, and 10 nM of I-1 on BRD9 degradation where actin was used as a control.
- FIG.5B is a Western Blot image of the effect of 500, 50, and 10 nM of I-2 on BRD9 degradation where actin was used as a control.
- FIG.5C is a Western Blot image of the effect of 500, 50, and 10 nM of I-3 on BRD9 degradation where actin was used as a contr
- FIG.5D is a Western Blot image of the effect of 500, 50, and 10 nM of I-8 on BRD9 degradation where actin was used as a control.
- FIG.5E is a Western Blot image of the effect of 500, 50, and 10 nM of I-7 on BRD9 degradation where actin was used as a control.
- FIG.5F is a Western Blot image of the effect of 500, 50, and 10 nM of I-13 on BRD9 degradation where actin was used as a control.
- FIG.6A is a Western Blot image of the effect of 500, 50, and 10 nM of I-14 on BRD9 degradation where actin was used as a control.
- FIG.6B is a Western Blot image of the effect of 500, 50, and 10 nM of I-9 on BRD9 degradation where actin was used as a control.
- FIG.6C is a Western Blot image of the effect of 500, 50, and 10 nM of I-5 on BRD9 degradation.
- FIG.6D is a Western Blot image of the effect of 500, 50, and 10 nM of I-17 on BRD9 degradation where actin was used as a control.
- FIG.7A is a Western Blot image of the effect of 500, 50, and 10 nM of I-12 on BRD9 degradation where actin was used as a control.
- FIG.7B is a Western Blot image of the effect of 500, 50, and 10 nM of I-15 on BRD9 degradation where actin was used as a control.
- FIG.7C is a Western Blot image of the effect of 500, 50, and 10 nM of I-23 on BRD9 degradation where actin was used as a control.
- FIG.7D is a Western Blot image of the effect of 500, 50, and 10 nM of I-24 on BRD9 degradation where actin was used as a control.
- FIG.7E is a Western Blot image of the effect of 500, 50, and 10 nM of I-25 on BRD9 degradation where actin was used as a control.
- FIG.8A is a high-resolution image showing compound I-8 overlaid with the crystal structure (PDB code 4UIV) of human BRD9 bromodomain with N-(1,1-dioxo-1-thian-4-yl)- 5-methyl-4- oxo-7-3-(trifluoromethyl)phenyl-4H,5H-thieno-3,2-c-pyridine-2- carboximidamide, a small molecule with a structure similar to the bromodomain targeting ligand portion of I-8.
- the two compounds have significant overlap confirming that I-8 has a conserved binding mode relative to the free bromodomain targeting ligand with the derivatized methoxy position projected to solvent. Hydrogen bonding to the key Asp residue is highlighted.
- FIG.8B is a dose-response curve comparing I-17 and I-25 in a BRD4-ligand displacement assay to determine selectivity st BRD4.
- the small molecule JQ1, a BRD4 inhibitor was used as a control.
- Compound I-25 which exhibited less activity at BRD4 than I-17, has increased selectivity against BRD4 compared to I-17.
- the x-axis is the compound concentration measured in log units and the y-axis is the normalized alpha signal measured in intensity.
- FIG.9A is a schematic representation of the degrader design based on the
- compound’ s interaction with the CRBN protein and the BRD9 protein.
- FIG.9B is a dose-response curve comparing I-1, I-2, and I-8 in a BRD9-ligand displacement assay to determine selectivity for BRD9.
- the x-axis is the compound concentration measured in log units and the y-axis is the normalized alpha signal measured in intensity.
- FIG.10A is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compounds I-1, I-2, I-8, and unmodified thalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of the compounds was decreased. All of the compounds were able to significantly induce formation of the complex relative to unmodified thalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.10B is an image of compound I-8 crystalized with the BRD9 protein.
- FIG.11A is an in-silico model of the assembly of the CRBN-DDB1 and BRD9 ligand-binding domains induced by compound I-8.
- the ternary assembly, including CRBN- DDB1 demonstrated the steric feasibility of ternary formation, with the two ligand-binding domains brought into close assembly by I-8.
- the crystal structure of I-8 with BRD9 ( Figure 10B) was docked into the published structure of CRBN-DDB1.
- FIG.11B are Western Blot images quantifying BRD9 and actin in a human AML-cell line (MOLM-13) by immunoblot after a 4 hour treatment with the indicated concentrations of compounds I-1, I-2, or I-8. Marked protein loss was observed at high concentrations of the potent dimerizers I-2 and I-8.
- FIG.12A is a dose-response curve measuring the formation of the BRD9:CRBN- DDB1 complex induced by I-1, I-8, I-5, and I-17 compared to unmodified thalidomide as detected by luminescence.
- the x-axis is compound concentration measured in log units and the y-axis is the normalized alpha signal measured in intensity.
- FIG.12B are Western Blot images quantifying BRD9 and actin in a human AML-cell line (MOLM-13) by immunoblot after a 4 hour treatment with the indicated concentrations of compounds I-5 and I-17. Both compounds were able to effectively downregulate BRD9 over a broad range of concentrations.
- FIG.13A is a Western Blog image quantifying BRD9 and actin in a human AML-cell line (MOLM-13) by immunoblot after 1, 2, 4, 16, and 24 hours with and without treatment of 100 nM of I-17 to assess the timecourse of degradation. Near complete BRD9 loss was observed within 1 hour of I-17 treatment, with no detectable return observed for the duration of the 24-hour treatment period. This profile is appropriate to enable study of primary consequences of acute BRD9 loss, as well as viability defects manifested over one or potentially more days.
- FIG.13B is a Western Blot image quantifying BRD9 and actin in human multiple myeloma (MM1S) cells by immunoblot.
- the cell lines were pretreated for 4 hours with vehicle (DMSO), I-BRD9 (a BRD9 inhibitor), lenalidomide, carfilzomib (a protease inhibitor), and MLN-4924 (a neddylation inhibitor) before exposure to 100 nM of I-17 to validate the cellular mechanism of I-17.
- Pretreatment with excess I-BRD9 or lenalidomide competed with I-17 for binding to BRD9 or CRBN and prevented degradation, consistent with a requirement for intracellular engagement of both targets.
- FIG.13C is a Western Blot image quantifying BRD9 and actin in MM1S WT cells and isogenic MMIS CRBN knockout cells (genetically edited by CRISP/Cas9) by immunoblot after a 4 hour treatment with the indicated doses of I-17 to establish a requirement of CRBN in degrading BRD9. While treatment of wild type MM.1S cells resulted in marked dose- dependent BRD9 loss, treatment of the MM.1S CRBNknockout cell line resulted in little to no BRD9 degradation, providing support for CRBN-dependent proteasomal degradation of BRD9 by I-17.
- FIG.14A is a dendrogram of the human bromodomain family organized into eight subfamilies.
- a single-point screen of I-17 at 32 members of the bromodomain family was conducted using BromoScan (experimental details are given in Example 6).
- the circles with corresponding percentages represent the percentage of bromodomain isolated on the solid support compared to control during the BromoScan.
- a control test without I-17 would result in 100% of broodomain on the solid support.
- Compound I-17 not only interacts with BRD9 as represented in the dendrogram, but also BRD7 and members of the BET family.
- FIG.14B are Western Blot images quantifying BRD9 and actin in a human AML-cell line (MOLM-13) by immunoblot after a 4 h eatment with the indicated concentrations of compound I-25. Compound I-25 induced BRD9 degradation over a broad range of concentrations.
- FIG.15A is a dendrogram of the human bromodomain family organized into eight subfamilies.
- a single-point screen of I-25 at 32 members of the bromodomain family was conducted using BromoScan (experimental details are given in Example 6).
- the circles with corresponding percentages represent the percentage of bromodomain isolated on the solid support compared to control during the BromoScan.
- a control test without I-25 would result in 100% of broodomain on the solid support.
- Compound I-25 exclusively interacts with BRD9.
- FIG.15B is a graph measuring the formation of the BRD9:CRBN-DDBI protein complex induced by compounds I-17, I-25, and unmodified pomalidomide as detected by luminescence.
- the luminescence signal was measured as the concentration of the compounds was decreased.
- Compounds I-17 and I-25 were able to significantly induce formation of the complex relative to unmodified pomalidomide.
- the x-axis is compound concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.16A is a graph measuring the formation of the BRD4:CRBN-DDBI protein complex induced by compounds I-17, I-25, and unmodified pomalidomide as detected by luminescence. The luminescence signal was measured as the concentration of the compounds was decreased. Compound I-25 exhibited selectivity for BRD9 and induced no formation of the BRD4:CRBN-DDBI protein complex. The x-axis is compound
- concentration measured in log units and the y-axis is the alpha signal measured in intensity.
- FIG.16B are Western Blot images quantifying BRD4 and tubulin in a human AML- cell line (MOLM-13) by immunoblot after a 4 hour treatment with the indicated
- FIG.17A are Western Blot images quantifying BRD7 and actin in a human AML-cell line (MOLM-13) by immunoblot after a 4 hour treatment with the indicated concentrations of compound I-17 and I-25.
- Compound I-25 was not able to induce degradation of BRD7 at any of the concentrations, but degradation was observed for I-17.
- FIG.17B is a dose-response curve of human AML (MOLM-13 cell line) cellular viability following 72 hour treatment with I-25 and I-17 compared to treatment with I-BRD9 and BI-7273, known BRD9 inhibitors.
- the x-axis is compound concentration measured in log units and the y-axis is normalized luminescence measured in intensity.
- FIG.18A is a dose-response curve of human AML (MV411 cell line) cellular viability following 72 hour treatment with I-25 and I-17 compared to treatment with I-BRD9 and BI-7273, known BRD9 inhibitors.
- the x-axis is compound concentration measured in log units and the y-axis is normalized luminescence measured in intensity. Experimental details are given in Example 13.
- FIG.18B is a dose-response curve of human multiple myeloma (MM1S) cellular viability following 72 hour treatment with I-25 and I-17 compared to treatment with I-BRD9 and BI-7273, known BRD9 inhibitors.
- the x-axis is compound concentration measured in log units and the y-axis is normalized luminescence measured in intensity. Experimental details are given in Example 13.
- FIG.19 is a dose-response curve of human multiple myeloma CRBN knockout (MM1S CRBN -/- ) cellular viability following 72 hour treatment with I-25 and I-17 compared to treatment with I-BRD9 and BI-7273, known BRD9 inhibitors.
- the x-axis is compound concentration measured in log units and the y-axis is normalized luminescence measured in intensity. Experimental details are given in Example 13. DETAILED DESCRIPTION
- the present application relates to novel bifunctional compounds, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
- the bifunctional com ound is of Formula X:
- Targeting Ligand is capable of binding to a targeted protein, such as a bromodomain-containing protein (e.g., BRD9);
- a targeted protein such as a bromodomain-containing protein (e.g., BRD9);
- the Linker is a group that covalently binds to the Targeting Ligand and the Degron;
- the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon).
- a ubiquitin ligase such as an E3 ubiquitin ligase (e.g., cereblon).
- the present application also relates to targeted degradation of proteins through the use of bifunctional compounds, including bifunctional compounds that link an E3 ubiquitin ligase-binding moiety to a ligand that binds the targeted proteins.
- the present application also relates to a bifunctional compound of Formula I:
- R 1 , R 2 , A, and n are each as defined herein;
- the Linker is a group that covalently binds to in Formula (I) and the Degron;
- the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (i.e., cereblon); and
- Targeting Ligand is capable of binding to a targeted protein, such as BRD9.
- the present application further relates to a Degron of Formula D1:
- the present application further relates to a Degron of Formula D2:
- the present application further relates to a Linker of Formula L1:
- the Linker is covalently bonded to a Degron via the next to Q, and covalently bonded to a Targeting Ligand via the next to Z 1 .
- the present application further relates to a Linker of Formula L2:
- the Linker is covalently bonded to a Degron via the next to Q 2 , and covalently bonded to the Targeting Ligand via the next to Z2.
- the present application further relates to a Linker of Formula L3:
- the Linker is covalently bonded to a Degron via the next to Q 3 , and covalently bonded to a Targeting Ligand via the next to Z 3 .
- Targeting Ligand (or target protein moiety or target protein ligand or ligand) is a small molecule which is capable of binding to a target protein of interest, such BRD9.
- a Targeting Ligand is a compound of Formula TL-I:
- A is phenyl or 5- or 6-membered heteroaryl containing 1 or 2 heteroatoms selected from N and S, wherein the phenyl or heteroaryl is optionally substituted with 1 to 3 R 3 ;
- R 1 is H, (C 1 -C 4 ) alkyl, or (C 1 -C 4 ) haloalkyl;
- each R 2 is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, OH, or NH 2 ;
- each R 3 is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 )
- haloalkoxy halogen, OH, NH 2 , or
- X 1 is NR 5 or O
- Y 1 is S(O) a or NR 5 ;
- each R 4 is independently (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, halogen, or -C(O)(C 1 - C 3 )alkyl;
- each R 5 is independently H or (C 1 -C 4 ) alkyl
- R 6 is H or (C 1 -C 4 ) alkyl
- a 0, 1, or 2;
- n and r are each independently 0, 1, 2, or 3; wherein the Targeting Ligand is bonded to the Linker via the next to
- A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
- each A is optionally substituted with 1 to 3 R 3 .
- A is or , wherein each A is optionally substituted with 1 to 3
- A is, , , , or , wherein
- each A is optionally substituted with 1 to 3 R3. In other embodiments, A is
- A is optionally substituted with 1 to 3 R 3 .
- A is optionally substituted with 1 to 3 R 3 .
- N substituted with 1 to 3 R3.
- A is optionally substituted with
- A is optionally substituted with 1 to 3 R3.
- N is optionally substituted with 1 to 3 R3.
- A is optionally substituted with 1 to 3 R 3 .
- A is , wherein each A is optionally substituted with 1 to
- A is optionally substituted with 1 to 3 R 3 . In other embodiments, A is optionally substituted with 1 to 3 R 3 . In other
- A is optionally substituted with 1 to 3 R 3 . In other embodiments, A is .
- R 1 is H, (C 1 -C 3 ) alkyl, or (C 1 -C 3 ) haloalkyl. In other embodiments, R 1 is H or (C 1 -C 4 ) alkyl. In other embodiments, R 1 is H, methyl, ethyl, n- propyl, or i-propyl. In other embodiments, R 1 is H, methyl or ethyl. In other embodiments, R 1 is H. In other embodiments, R 1 is (C 1 -C 4 ) alkyl. In other embodiments, R 1 is methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R 1 is methyl or ethyl. In other embodiments, R 1 is (C 1 -C 4 ) alkyl or (C 1 -C 4 ) haloalkyl.
- At least one R 2 is (C 1 -C 3 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 3 ) alkoxy, (C1-C3) haloalkoxy, halogen, OH, or NH2.
- at least one R2 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, or halogen.
- at least one R2 is halogen, OH, or NH2.
- At least one R2 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, or (C 1 -C 4 ) haloalkoxy.
- at least one R 2 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, or halogen.
- at least one R 2 is (C 1 -C 4 ) alkoxy or halogen.
- at least one R 2 is (C 1 -C 4 ) alkoxy.
- at least one R 2 is (C 1 -C 3 ) alkoxy.
- At least one R 2 is methoxy, ethoxy, n-propoxy, or i-propoxy. In other embodiments, at least one R 2 is methoxy or ethoxy. In other embodiments, at least one R 2 is methoxy.
- At least one R 3 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 )
- At least one R 3 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkox halo en OH, or NH 2 . In some embodiments, at least one R 3 is In other embodiments, at least one R 3 is (C 1 -C 4 ) alkyl, (C 1 -C 4 )
- haloalkyl (C 1 -C 4 ) alkoxy, or (C 1 -C 4 ) haloalkoxy.
- at least one R 3 is (C 1 -C 4 ) alkyl, halogen, OH, or NH 2 .
- at least one R 3 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halogen, OH, or NH 2 .
- At least one R 3 is (C 1 -C 3 ) alkyl, (C 1 -C 3 ) haloalkyl, (C 1 -C 3 ) alkoxy, (C 1 -C 3 ) haloalkoxy, halogen, OH, or NH 2 .
- X 1 is NR 5 . In other embodiments, X 1 is NH. In other embodiments, X 1 is O.
- Y1 is S(O)a. In other embodiments, Y1 is S(O)2. In other embodiments, Y 1 is S(O). In other embodiments, Y 1 is S. In other embodiments, Y 1 is NR 5 .
- At least one R4 is (C1-C3) alkyl, (C1-C3) haloalkyl, halogen, or - C(O)(C 1 -C 3 )alkyl. In other embodiments, at least one R 4 is (C 1 -C 3 ) alkyl, (C 1 -C 3 ) haloalkyl, or halogen. In other embodiments, at least o 4 is (C 1 -C 3 ) alkyl, (C 1 -C 3 ) haloalkyl, or - C(O)(C 1 -C 3 )alkyl.
- At least one R 4 is (C 1 -C 3 ) alkyl, halogen, or - C(O)(C 1 -C 3 )alkyl. In other embodiments, at least one R 4 is (C 1 -C 3 ) alkyl or -C(O)(C 1 - C 3 )alkyl. In other embodiments, at least one R 4 is (C 1 -C 3 ) alkyl or halogen.
- R 5 is H or (C 1 -C 3 ) alkyl. In other embodiments, R 5 is H. In other embodiments, R5 is (C1-C4) alkyl. In other embodiments, R5 is (C1-C3) alkyl. In other embodiments, R 5 is H, methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R 5 is H, methyl, or ethyl. In other embodiments, R5 is methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R 5 is methyl or ethyl.
- R 6 is H or (C 1 -C 3 ) alkyl. In other embodiments, R 6 is H. In other embodiments, R 6 is (C 1 -C 4 ) alkyl. In other embodiments, R 6 is (C 1 -C 3 ) alkyl. In other embodiments, R 6 is H, methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R 6 is H, methyl, or ethyl. In other embodiments, R 6 is methyl, ethyl, n-propyl, or i-propyl. In other embodiments, R 6 is methyl or ethyl.
- a is 0. In other embodiments, a is 1. In other embodiments, a is 2. In other embodiments, a is 0 or 1. In other embodiments, a is 1 or 2.
- n is 0. In other embodiments, n is 1. In other embodiments, n is 2. In other embodiments, n is 3. In other embodiments, n is 0 or 1. In other embodiments, n is 1 or 2. In other embodiments, n is 0, 1 or 2. In other embodiments, n is 1, 2 or 3.
- r is 0. In other embodiments, r is 1. In other embodiments, r is 2. In other embodiments, r is 3. In other embodiments, r is 0 or 1. In other embodiments, r is 1 or 2. In other embodiments, r is 0, 1 or 2. In other embodiments, r is 1, 2 or 3.
- any of the groups described herein for any of A, X 1 , Y 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , a, n, and r can be combined with any of the groups described herein for one or more of the remainder of A, X1, Y1, R1, R2, R3, R4, R5, R6, a, n, and r, and may further be combined with any of the groups described herein for the Linker.
- A is and R 3 is 6
- A is R 3 is , and X 1 is NR 5 .
- A is and X 1 is NH.
- A is and X 1 is O.
- A is and Y 1 is S.
- A is and Y 1 is S(O).
- A is and Y 1 is S(O)2.
- A is X 1 is NR 5 , and Y1 is S.
- A is X 1 is NR 5 , and Y 1 is S(O).
- A is X 1 is NR 5 , and Y 1 is S(O) 2 .
- A is X 1 is NH, and Y 1 is S.
- A is X 1 is NH, and Y 1 is S(O).
- A is X 1 is NH, and Y 1 is S(O) 2 .
- A is X 1 is O, and Y 1 is S.
- A is X1 is O, and Y 1 is S(O).
- A is X 1 is O, and Y 1 is S(O) 2 .
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 1 is H.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 1 is (C 1 -C 4 ) alkyl.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 1 is methyl.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 1 is ethyl.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 2 is (C 1 -C 4 ) alkoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), and R 2 is (C 1 -C 4 ) methoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is H, and R C 1 -C 4 ) alkoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is H, and R 2 is (C 1 -C 4 ) methoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is (C 1 -C 4 ) alkyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A, R3, X1, and Y1 are each as defined, where applicable, in any one of (1)-(16), R 1 is (C 1 -C 4 ) alkyl, and R 2 is methoxy.
- A, R3, X1, and Y1 are each as defined, where applicable, in any one of (1)-(16), R 1 is methyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is methyl, and R 2 is methoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is ethyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A, R 3 , X 1 , and Y 1 are each as defined, where applicable, in any one of (1)-(16), R 1 is ethyl, and R 2 is methoxy.
- A, R 1 , R 3 , X 1 , and Y 1 are each as defined in any one of (17)-(20), and n is 1.
- A, R 1 , R 3 , X 1 , and Y 1 are each as defined in any one of (17)-(20), and n is 2.
- A, R 2 , R 3 , X 1 , and Y 1 are each as defined in (21) or (22), and n is 1.
- A, R 2 , R 3 , X 1 , and Y 1 are each as defined in (21) or (22), and n is 2.
- A, R 1 , R 2 , R 3 , X 1 , and Y 1 are each as defined in any one of (23)-(30), and n is 1.
- A, R 1 , R 2 , R 3 , X 1 , and Y 1 are each as defined in any one of (23)-(30), and n is 2.
- A, R 1 , R 2 , R 3 , X 1 , Y 1 , and n are each as defined, where applicable, in any one of (31)-(36), and r is 0.
- A, R 1 , R 2 , R 3 , X 1 , Y 1 , n, and r are each as defined, where applicable, in any one of (31)-(37), and R 6 is H.
- A, R 1 , R 2 , R 3 , X 1 , Y 1 , n, and r are each as defined, where applicable, in any one of (31)-(37), and R 6 is methyl.
- R 6 is methyl.
- A is and R 1 is (C 1 -C 4 ) alkyl.
- A is , R 1 is (C 1 -C 4 ) alkyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A is , R 1 is (C 1 -C 4 ) alkyl, and R 2 is methoxy.
- A is and R1 ismethyl.
- A is , R 1 is methyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A is , R 1 is methyl, and R 2 is methoxy.
- A is and R 1 is ethyl.
- A is , R 1 is ethyl, and R 2 is (C 1 -C 4 ) alkoxy.
- A is , R 1 is ethyl, and R 2 is methoxy.
- A is and R 1 is H.
- A is , R 1 is H, and R 2 is (C 1 -C 4 ) alkoxy.
- A is , R 1 is H, and R 2 is methoxy.
- A, R 1 , and R 3 are each as defined, where applicable, in any one of (40)-(51), and n is 1.
- A, R 1 , and R 3 are each as defined, where applicable, in any one of (40)-(51), and n is 2.
- R1 is (C1-C4) alkyl and R2 is (C1-C4) alkoxy.
- R 1 is (C 1 -C 3 ) alkyl and R 2 is (C 1 -C 3 ) alkoxy.
- R1 is (C1-C4) alkyl and R2 is methoxy.
- R 1 is methyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is ethyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is methyl and R 2 is methoxy.
- R 1 is ethyl and R 2 is methoxy.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 1.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is methyl
- R 2 is methoxy
- n is 1.
- R 1 is ethyl
- R 2 is methoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 2.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R1 is methyl
- R2 is methoxy
- n is 2.
- R 1 is ethyl
- R 2 is methoxy
- n is 2.
- X 1 , Y 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , a, n, and r are each as defined above in Formula TL-I.
- R 1 is (C 1 -C 4 ) alkyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is (C 1 -C 3 ) alkyl and R 2 is (C 1 -C 3 ) alkoxy.
- R 1 is (C 1 -C 4 ) alkyl and R 2 is methoxy.
- R 1 is methyl and R 2 is (C 1 -C 4 ) alkoxy.
- R1 is ethyl and R2 is (C1-C4) alkoxy.
- R 1 is methyl and R 2 is methoxy.
- R1 is ethyl and R2 is methoxy.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 1.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is methyl
- R 2 is methoxy
- n is 1.
- R 1 is ethyl
- R 2 is methoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 2.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is methyl
- R 2 is methoxy
- n is 2.
- R 1 is ethyl
- R 2 is methoxy
- n is 2.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and X 1 is NR 5 .
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), and X 1 is NH.
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O.
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S(O) 2 .
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NR 5 , and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NR 5 , and Y 1 is S(O).
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NR 5 , and Y 1 is S(O) 2 .
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NH, and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NH, and Y 1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NH, and Y 1 is S(O) 2 .
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O, and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O, and Y 1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O, and Y 1 is S(O) 2 .
- X 1 is NR 5 and Y 1 is S(O) 2 .
- X 1 is NH and Y 1 is S(O) 2 .
- X 1 is O and Y 1 is S(O) 2 .
- X 1 and Y 1 are each as defined in any one of (37)-(39), and r is 0.
- X1 and Y1 are each as defined in any one of (37)-(39), and r is 1.
- X1 and Y1 are each as defined in any one of (37)-(39), and r is 2.
- X1, Y1, and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is (C 1 -C 4 ) alkyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is methyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is ethyl.
- R 1 is ethyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 2 is (C 1 -C 4 ) alkoxy.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 2 is (C 1 -C 4 ) ethoxy.
- X1, Y1, R1, R2, and r are each as defined, where applicable, in any one of (37)-(47), and n is 1.
- X1, Y1, R1, R2, and r are each as defined, where applicable, in any one of (37)-(47), and n is 2.
- X 1 , Y 1 , R 1 , R 2 , R 4 , R 5 , R 6 , a, n, and r can each be selected from any of the groups and combined as described above in Formula TL-I.
- X 1 , Y 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , a, n, and r are each as defined above in Formula TL-I.
- R 1 is (C 1 -C 4 ) alkyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is (C 1 -C 3 ) alkyl and R 2 is (C 1 -C 3 ) alkoxy.
- R 1 is (C 1 -C 4 ) alkyl and R 2 is methoxy.
- R 1 is methyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is ethyl and R 2 is (C 1 -C 4 ) alkoxy.
- R 1 is methyl and R 2 is methoxy.
- R 1 is ethyl and R 2 is methoxy.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 1.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 1.
- R 1 is methyl
- R 2 is methoxy
- n is 1.
- R 1 is ethyl
- R 2 is methoxy
- n is 1.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 3 ) alkyl
- R 2 is (C 1 -C 3 ) alkoxy
- n is 2.
- R 1 is (C 1 -C 4 ) alkyl
- R 2 is methoxy
- n is 2.
- R 1 is methyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R 1 is ethyl
- R 2 is (C 1 -C 4 ) alkoxy
- n is 2.
- R1 is methyl
- R2 is methoxy
- n is 2.
- R 1 is ethyl
- R 2 is methoxy
- n is 2.
- R1, R2, and n are each as defined, where applicable, in any one of (1)-(21), and X 1 is NR 5 .
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and X 1 is NH.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), and Y 1 is S(O) 2 .
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NR 5 , and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NR 5 , and Y 1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X1 is NR5, and Y1 is S(O)2.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X1 is NH, and Y1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X1 is NH, and Y1 is S(O).
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is NH, and Y 1 is S(O) 2 .
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O, and Y 1 is S.
- R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is nd Y 1 is S(O). (36) In one embodiment, R 1 , R 2 , and n are each as defined, where applicable, in any one of (1)-(21), X 1 is O, and Y 1 is S(O) 2 .
- X 1 is NR 5 and Y 1 is S(O) 2 .
- X 1 is NH and Y 1 is S(O) 2 .
- X1 is O and Y1 is S(O)2.
- X 1 and Y 1 are each as defined in any one of (37)-(39), and r is 0.
- X 1 and Y 1 are each as defined in any one of (37)-(39), and r is 1.
- X 1 and Y 1 are each as defined in any one of (37)-(39), and r is 2.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is (C 1 -C 4 ) alkyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is methyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 1 is ethyl.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 2 is (C 1 -C 4 ) alkoxy.
- X 1 , Y 1 , and r are each as defined, where applicable, in any one of (37)-(42), and R 2 is (C 1 -C 4 ) ethoxy.
- X 1 , Y 1 , R 1 , R 2 , and r are each as defined, where
- X1, Y1, R1, R2, and r are each as defined, where
- n is 2.
- X1, Y1, R1, R2, R4, R5, R6, a, n, and r can each be selected from any of the groups and combined as described above in Formula TL-I.
- T Targeting Ligand having the one of structures in Table A:
- the Degron serves to link a targeted protein, through a Linker and a Targeting Ligand, to a ubiquitin ligase for proteosomal degradation.
- the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase.
- the Degron is capable of binding to cereblon.
- the Degron is of Formula D1:
- Y is a bond, (CH 2 ) 1-6 , (CH 2 ) 0-6 -O, (CH 2 ) 0-6 -C(O)NR 11 , (CH 2 ) 0-6 -NR 11 C(O), (CH 2 ) 0-6 -
- R 11 is H or C 1 -C 6 alkyl
- R 12 is C 1 -C 6 alkyl or C(O)-C 1 -C 6 alkyl
- R 15 is H, deuterium, C 1 -C 3 alkyl, F, or Cl;
- each R 16 is independently halogen, OH, C 1 -C 6 alkyl, or C 1 -C 6 alkoxy;
- q 0, 1, or 2;
- v is 0, 1, 2, or 3, wherein the Degron is covalently bonded to the Linker via .
- Z is C(O).
- Z is C(O) or CH 2 .
- Z is C(R 13 ) 2 ; and each R 13 is H. In one embodiment, Z is C(R 13 ) 2 ; and one of R 13 is H, and the other is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl. In one embodiment, Z is C(R 13 ) 2 ; and each R 13 is independently selected from methyl, ethyl, and propyl.
- Y is a bond
- Y is a bond, O, or NH.
- Y is (CH 2 ) 1 , (CH 2 ) 2 , (CH 2 ) 3 , (CH 2 ) 4 , (CH 2 ) 5 , or (CH 2 ) 6 .
- Y is (CH2)1, (CH2)2, or (CH2)3.
- Y is (CH2)1 or (CH2)2.
- Y is O, CH 2 -O, (CH 2 ) 2 -O, (CH 2 ) 3 -O, (CH 2 ) 4 -O, (CH 2 ) 5 -O, or (CH 2 ) 6 -O.
- Y is O, CH 2 -O, (CH 2 ) 2 -O, or (CH 2 ) 3 -O.
- Y is O or CH 2 -O.
- Y is O.
- Y is C(O)NR 11 , CH 2 -C(O)NR 11 , (CH 2 ) 2 -C(O)NR 11 , (CH 2 ) 3 - C(O)NR 11 , (CH 2 ) 4 -C(O)NR 11 , (CH 2 ) 5 -C(O)NR 11 , or (CH 2 ) 6 -C(O)NR 11 .
- Y is C(O)NR 11 , CH 2 -C(O)NR 11 , (CH 2 ) 2 -C(O)NR 11 , or (CH 2 ) 3 -C(O)NR 11 .
- Y is C(O)NR 11 or CH 2 -C(O)NR 11 .
- Y is C(O)NR 11 .
- Y is NR 11 C(O), CH 2 -NR 11 C(O), (CH 2 ) 2 -NR 11 C(O), (CH 2 ) 3 - NR 11 C(O), (CH 2 ) 4 -NR 11 C(O), (CH 2 ) 5 -NR 11 C(O), or (CH 2 ) 6 -NR 11 C(O).
- Y is NR 11 C(O), CH 2 -NR 11 C(O), (CH 2 ) 2 -NR 11 C(O), or (CH 2 ) 3 -NR 11 C(O).
- Y is NR 11 C(O) or CH 2 -NR 11 C(O).
- Y is NR 11 C(O).
- R 11 is H. In one embodiment, R 11 is selected from methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In one embodiment, R 11 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Y is NH, CH 2 -NH, (CH 2 ) 2 -NH, (CH 2 ) 3 -NH, (CH 2 ) 4 -NH, (CH 2 ) 5 - NH, or (CH 2 ) 6 -NH.
- Y is NH, CH 2 -NH, (CH 2 ) 2 -NH, or (CH 2 ) 3 -NH.
- Y is NH or CH 2 -NH.
- Y is NH.
- Y is NR 12 , CH 2 -NR 12 , (CH 2 ) 2 -NR 12 , (CH 2 ) 3 -NR 12 , (CH 2 ) 4 -NR 12 , (CH 2 ) 5 -NR 12 , or (CH 2 ) 6 -NR 12 .
- Y is NR 12 , CH 2 -NR 12 , (CH 2 ) 2 -NR 12 , or (CH 2 ) 3 -NR 12 .
- Y is NR 12 or CH 2 -NR 12 .
- Y is NR 12 .
- R 12 is selected from methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl. In one embodiment, R12 is C1-C3 alkyl selected from methyl, ethyl, and propyl.
- R12 is selected from C(O)-methyl, C(O)-ethyl, C(O)-propyl, C(O)-butyl, C(O)-i-butyl, C(O)-t-butyl, C(O)-pentyl, C(O)-i-pentyl, and C(O)-hexyl.
- R 12 is C(O)-C 1 -C 3 alkyl selected from C(O)-methyl, C(O)-ethyl, and C(O)- propyl.
- R 13 is H.
- R 13 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl. In one embodiment, R 13 is methyl.
- q is 0.
- q is 1.
- q is 2.
- each R 14 is independently C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- v is 0.
- v is 1.
- v is 2.
- v is 3.
- each R 16 is independently selected from halogen (e.g., F, Cl, Br, and I), OH, C1-C6 alkyl (e.g., methyl, ethyl, propyl, butyl, i-butyl, t-butyl, pentyl, i-pentyl, and hexyl), and C 1 -C 6 alkoxy (e.g., methoxy, ethoxy, propoxy, butoxy, i-butoxy, t-butoxy, and pentoxy).
- each R16 is independently selected from F, Cl, OH, methyl, ethyl, propyl, butyl, i-butyl, t-butyl, methoxy, and ethoxy.
- R15 is H, deuterium, or C1-C3 alkyl. In another embodiment, R15 is H or C 1 -C 3 alkyl. In a further embodiment, R 15 is in the (S) or (R) configuration. In a further embodiment, R 15 is in the (S) configuration. In one embodiment, the compound comprises a racemic mixture of (S)-R 15 and (R)-R 15 .
- R 15 is H.
- R 15 is deuterium. In one embodiment, R 15 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl. In one embodiment, R 15 is methyl.
- R 15 is F or Cl. In a further embodiment, R 15 is in the (S) or (R) configuration. In a further embodiment, R 15 is in the (R) configuration. In one embodiment, the compound comprises a racemic mixture of (S)-R15 and (R)-R15. In one embodiment, R15 is F.
- any of the groups described herein for any of Y, Z, R11, R12, R13, R14, R15, R16, q and v can be combined with any of the groups described herein for one or more of the remainder of Y, Z, R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , q and v, and may further be combined with any of the groups described herein for the Linker.
- Z is C(O) and Y is a bond.
- Z is C(O) and Y is NH.
- Z is C(O) and Y is (CH 2 ) 0-6 -O. In a further embodiment, Y is O.
- Z is C(O); Y is a bond; and q and v are each 0.
- Z is C(O); Y is NH; and q and v are each 0.
- Z is C(O); Y is (CH 2 ) 0-6 -O; and q and v are each 0. In a further embodiment, Y is O.
- Z is C(O); Y is a bond; and R 13 is H.
- Z is C(O); Y is a bond; and R 15 is H.
- Z is C(O); Y is NH; and R 13 is H.
- Z is C(O); Y is NH; and R 15 is H.
- Z is C(O); Y is a bond; R13 is H; and R15 is H.
- Z is C(O); Y is NH; R 13 is H; and R 15 is H.
- Z is C(O); Y is (CH2)0-6-O; and R13 is H. In a further embodiment, Y is O.
- Z is C(O); Y is (CH2)0-6-O; and R15 is H. In a further embodiment, Y is O.
- Z is C(O); Y is (CH 2 ) 0-6 -O; R 13 is H; and R 15 is H. In a further embodiment, Y is O.
- q and v are each 0; and Y, Z, R 13 , R 15 , and R 16 are each as defined in any of (1)– (3) and (7)– (15).
- Z is CH Y is a bond.
- Z is CH 2 and Y is NH.
- Z is CH 2 and Y is (CH 2 ) 0-6 -O. In a further embodiment, Y is O.
- Z is CH 2 ; Y is a bond; and q and v are each 0.
- Z is CH2; Y is NH; and q and v are each 0.
- Z is CH 2 ; Y is (CH 2 ) 0-6 -O; and q and v are each 0. In a further embodiment, Y is O.
- Z is CH 2 ; Y is a bond; and R 13 is H.
- Z is CH 2 ; Y is a bond; and R 15 is H.
- Z is CH 2 ; Y is NH; and R 13 is H.
- Z is CH 2 ; Y is NH; and R 15 is H.
- Z is CH 2 ; Y is a bond; R 13 is H; and R 15 is H.
- Z is CH 2 ; Y is NH; R 13 is H; and R 15 is H.
- Z is CH 2 ; Y is (CH 2 ) 0-6 -O; and R 13 is H. In a further embodiment, Y is O.
- Z is CH 2 ; Y is (CH 2 ) 0-6 -O; and R 15 is H. In a further embodiment, Y is O.
- Z is CH 2 ; Y is (CH 2 ) 0-6 -O; R 13 is H; and R 15 is H. In a further embodiment, Y is O.
- q and v are each 0; and Y, Z, R 13 , R 15 , and R 16 are each as defined in any of (17)– (19) and (23)– (31).
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l:
- Y is a bond, O, or NH. In one embodiment, Y is a bond. In one embodiment, Y is O. In one embodiment, Y is NH.
- the Degron is of Formula D2:
- Z4 is absent or C(O);
- each R 17 is independently C 1 -C 3 alkyl
- q' is 0, 1, 2, 3 or 4;
- R 18 is H or C 1 -C 3 alkyl, he Degron is covalently bonded to another moiety (e.g., a compound, or a Linker)
- Z 4 is absent.
- Z 4 is C(O).
- q' is 0.
- q' is 1.
- q' is 2.
- q' is 3.
- each R 17 is independently C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- R 18 is methyl, ethyl, or propyl. In one embodiment, R 18 is methyl.
- the Degron is of Formula D2a:
- each R 17 is independently C 1 -C 3 alkyl
- q' is 0, 1, 2, 3 or 4;
- R 18 is H or C 1 -C 3 alkyl
- Degron is covalently bonded to another moiety (e.g., a compound, or a Linker)
- another moiety e.g., a compound, or a Linker
- q' is 0.
- q' is 1.
- q' is 2.
- q' is 3.
- each R 17 is independently C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- R 18 is methyl, ethyl, or propyl. In one embodiment, R 18 is methyl. In one embodiment, the Degron is of Formula D2b:
- each R17 is independently C1-C3 alkyl
- q' is 0, 1, 2, 3 or 4;
- R18 is H or C1-C3 alkyl
- Degron is covalently bonded to another moiety (e.g., a compound, or a Linker)
- another moiety e.g., a compound, or a Linker
- q' is 0.
- q' is 1.
- q' is 2.
- q' is 3.
- each R17 is independently C1-C3 alkyl selected from methyl, ethyl, and propyl.
- R18 is methyl, ethyl, or propyl. In one embodiment, R18 is methyl.
- Linker is a bond, a carbon chain, carbocyclic ring, or heterocyclic ring that serves to link a Targeting Ligand with a Degron.
- the carbon chain optionally comprises one, two, three, or more heteroatoms selected from N, O, and S.
- the carbon chain comprises only saturated chain carbon atoms.
- the carbon chain optionally comprises two or more unsaturated chain carbon atoms (e.g., C C or C C ).
- one or more chain carbon atoms in the carbon chain are optionally substituted with one or more substituents (e.g., oxo, C1-C6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkoxy, OH, halogen, NH 2 , NH(C 1 -C 3 alkyl), N(C 1 -C 3 alkyl) 2 , CN, C 3 -C 8 cycloalkyl, heterocyclyl, phenyl, and heteroaryl).
- substituents e.g., oxo, C1-C6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkoxy, OH, halogen, NH 2 , NH(C 1 -C 3 alkyl), N(C 1 -C 3 alkyl) 2 , CN, C 3 -C
- the Linker comprises at least 5 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises less than 25 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises less than 20 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 chain atoms (e.g., C, O, N, and S).
- the Linker comprises 5, 7, 9, 11, 13, 15, 17, or 19 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 5, 7, 9, or 11 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 11, 13, 15, 17, or 19 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 11, 13, 15, 17, 19, 21, or 23 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 6, 8, 10, 12, 14, 16, 18, 20, 22, or 24 chain atoms (e.g., C, O, N, and S).
- the Linker comprises 6, 8, 10, 12, 14, 16, 18, or 20 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 6, 8, 10, or 12 chain atoms (e.g., C, O, N, and S). In one embodiment, the Linker comprises 12, 14, 16, 18, or 20 chain atoms (e.g., C, O, N, and S).
- the Linker comprises from 11 to 19 chain atoms (e.g., C, O, N, and S).
- the Linker is a carbon chain optionally substituted with non- bulky substituents (e.g., oxo, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 3 alkoxy, OH, halogen, NH 2 , NH(C 1 -C 3 alkyl), N(C 1 -C 3 alkyl) 2 , and CN).
- the non- bulky substitution is located on the chain carbon atom proximal to the Degron (i.e., the carbon atom is separated from the carbon atom to which the Degron is bonded by at least 3, 4, or 5 chain atoms in the Linker).
- the non-bulky substitution is located on the chain carbon atom proximal to the Ta ng Ligand (i.e., the carbon atom is separated from the carbon atom to which the Degron is bonded by at least 3, 4, or 5 chain atoms in the Linker).
- p1 is an integer selected from 0 to 12;
- p2 is an integer selected from 0 to 12;
- p3 is an integer selected from 1 to 6;
- each W is independently absent, CH 2 , O, S, or NR 19 ;
- Z 1 is absent, C(O), CH 2 , O, (CH 2 ) j NR 19 , O(CH 2 ) j C(O)NR 19 , C(O)NR 19 ,
- each R 19 is independently H or C 1 -C 3 alkyl
- s1 and s2 are each independently 1, 2, or 3;
- j is 1, 2, or 3;
- k is 1, 2, or 3;
- Q is absent, NHC(O)CH 2 , or O(CH 2 ) 1-2 ; wherein the Linker is covalently bonded to a Degron via the next to Q, and covalently bonded to a Targeting Ligand via the next to Z 1 .
- the total number of chain atoms in the Linker is less than 30. In a further embodiment, the total number of chain atoms in the Linker is less than 20.
- p1 is an integer selected from 0 to 10.
- p1 is an integer selected from 1 to 10.
- p1 is selected from 1, 2, 3, 4, 5, and 6.
- p1 is 0, 1, 3, or 5.
- p1 is 0, 1, 2, or 3.
- p1 is 0.
- p1 is 1.
- p1 is 2.
- p1 is 3.
- p1 is 4.
- p1 is 5.
- p2 is an integer selected from 0 to 10.
- p2 is selected from 0, 1, 2, 3, 4, 5, and 6.
- p2 is 0, 1, 2, or 3.
- p2 is 0.
- p2 is 1.
- p2 is 2.
- p2 is 3.
- p3 is an integer selected from 1 to 5.
- p3 is 2, 3, 4, or 5.
- p3 is 0, 1, 2, or 3.
- p3 is 0.
- p3 is 1.
- p3 is 2.
- p3 is 3.
- p3 is 4.
- At least one W is CH 2 .
- At least one W is O.
- At least one W is S.
- At least one W is NH.
- At least one W is NR 19 ; and each R 19 is independently C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- each W is O.
- each W is CH2.
- j is 1, 2, or 3.
- j is 1.
- j is 2.
- j 3.
- j is 2 or 3.
- j is 1 or 2.
- k is 1, 2, or 3.
- k is 1.
- k is 2.
- k is 3.
- k is 2 or 3.
- k is 1 or 2.
- Q is absent.
- Q is NHC(O)CH 2 .
- Q is O(CH 2 ) 1-2 .
- Q is OCH 2 .
- Q is OCH 2 CH 2 .
- Z 1 is absent.
- Z 1 is O(CH 2 ) j C(O)NR 19 ; and R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 1 is O(CH 2 ) j C(O)NR 19 ; and R 19 is H.
- Z 1 is O(CH 2 ) j C(O)NR 19 ;
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1.
- Z 1 is O(CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 1.
- Z 1 is O(CH 2 ) j C(O)NR 19 ;
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2.
- Z 1 is O(CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 2.
- Z 1 is O(CH 2 ) j C(O)NR 19 ;
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 3.
- Z1 is O(CH2)jC(O)NR19; and R19 is H; and j is 3.
- Z 1 is C(O)NR 19 ; and R 19 is H.
- Z1 is C(O)NR19; and R19 is C1-C3 alkyl selected from methyl, ethyl, and propyl.
- Z1 is (CH2)jC(O)NR19; and R19 is H.
- Z 1 is (CH 2 ) j C(O)NR 19 ; and R 19 is C 1 -C 3 alkyl selected from
- Z 1 is (CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 1.
- Z 1 is (CH 2 ) j C(O)NR 19 ;
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1
- Z 1 is (CH 2 ) j C(O 9 ; R 19 is H; and j is 2.
- Z 1 is (CH 2 ) j C(O)NR 19 ; R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2.
- Z 1 is (CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 3.
- Z 1 is (CH 2 ) j C(O)NR 19 ;
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 3.
- Z 1 is NR 19 C(O); and R 19 is H.
- Z1 is NR19C(O); and R19 is C1-C3 alkyl selected from methyl, ethyl, and propyl.
- Z 1 is (CH 2 ) j NR 19 C(O); and R 19 is H.
- Z 1 is (CH 2 ) j NR 19 C(O); and R 19 is C 1 -C 3 alkyl selected from
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is H; and j is 1.
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is H; and j is 2.
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2.
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is H; and j is 3.
- Z 1 is (CH 2 ) j NR 19 C(O); R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 3.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; and each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; and one of R 19 is H and one of R19 is C1-C3 alkyl selected from methyl, ethyl, and propyl.
- Z1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NH.
- Z1 is (CH2)kNR19(CH2)jC(O)NR19; each R19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1.
- Z1 is (CH2)kNR19(CH2)jC(O)NR19; each R19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and k is 1.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; j is 1; and k is 1.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1.
- Z 1 is (CH 2 ) k NR 19 (CH 2 )C(O)NH.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and k is 1.
- Z 1 is (CH 2 )NR 19 (CH 2 ) j C(O)NH.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C1-C3 alkyl selected from methyl, ethyl, and propyl; j is 1; and k is 1.
- Z 1 is (CH 2 )NR 19 (CH 2 )C(O)NH.
- Z 1 is
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and k is 2.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2. In one embodiment, Z 1 is (CH 2 ) k NR 19 (CH 2 ) 2 C(O)NH.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and k is 2. In one embodiment, Z 1 is (CH 2 ) 2 NR 19 (CH 2 ) j C(O)NH.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 3.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; each R 19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and k is 3.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j is 3. In one embodiment, Z 1 is (CH2)kNR19(CH2)3C(O)NH.
- Z 1 is (CH 2 ) k NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C1-C3 alkyl selected from methyl, ethyl, and propyl; and k is 3.
- Z1 is (CH 2 ) 3 NR 19 (CH 2 ) j C(O)NH.
- Z1 is NR19(CH2)jC(O)NR19; and each R19 is independently H or C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; and each R 19 is H.
- Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 - C 3 alkyl selected from methyl, ethyl, and propyl; and j is 1.
- Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 1. (100) In one embodiment, Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 - C 3 alkyl selected from methyl, ethyl, and propyl; and j is 2.
- (101) in one embodiment, is NR 19 (CH 2 ) j C(O)NR 19 ; R 19 is H; and j is 2.
- Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; one of R 19 is H and one of R 19 is C 1 - C3 alkyl selected from methyl, ethyl, and propyl; and j is 3.
- Z 1 is NR 19 (CH 2 ) j C(O)NR 19 ; and R 19 is H; and j is 3.
- Z 1 and R 19 are as defined in (104), and s1 is 1.
- Z1 and R19 are defined in (104), s1 is 1; and s2 is 1.
- Z 1 is as defined in (104), s1 is 1; and s2 is 2.
- Z1 and R19 are as defined in (104), s1 is 1; and s2 is 3.
- Z 1 and R 19 are as defined in (104), and s1 is 2.
- Z 1 and R 19 are as defined in (104), s1 is 2; and s2 is 1.
- Z 1 and R 19 are as defined in (104), s1 is 2; and s2 is 2.
- Z 1 and R 19 are as defined in (104), s1 is 2; and s2 is 3.
- Z 1 and R 19 are as defined in (104), and s1 is 3.
- Z 1 and R 19 are as defined in (104), s1 is 3; and s2 is 1.
- Z 1 and R 19 are as defined in (104), s1 is 3; and s2 is 2.
- Z 1 and R 19 are as defined in (104), s1 is 3; and s2 is 3.
- Z 1 and R 19 are as defined in (104), s1 is 1; s2 is 1; and j is 1.
- Z 1 and R 19 are as defined in (104), s1 is 1; s2 is 1; and j is 2.
- Z 1 and R 19 are as defined in (104), s1 is 1; s2 is 1; and j is 3.
- R 19 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 1 and R 19 are as defined in (120), and s1 is 1.
- Z 1 and R 19 are as defined in (120), s1 is 1; and s2 is 1.
- Z 1 and R 19 are as defined in (120), s1 is 1; and s2 is 2.
- Z 1 and R 19 are as defined in (120), s1 is 1; and s2 is 3.
- Z 1 and R 19 are as defined in (120), and s1 is 2. (126) In one embodiment, Z 1 and R 19 are as defined in (120), s1 is 2; and s2 is 1.
- Z 1 and R 19 are as defined in (120), s1 is 2; and s2 is 2.
- Z 1 and R 19 are as defined in (120), s1 is 2; and s2 is 3.
- Z 1 and R 19 are as defined in (120), and s1 is 3.
- Z1 and R19 are as defined in (120), s1 is 3; and s2 is 1.
- Z 1 and R 19 are as defined in (120), s1 is 3; and s2 is 2.
- Z1 and R19 are as defined in (120), s1 is 3; and s2 is 3.
- Z 1 and R 19 are as defined in (120), s1 is 1; s2 is 1; and j is 1.
- Z 1 and R 19 are as defined in (120), s1 is 1; s2 is 1; and j is 2.
- Z 1 is part of the Targeting Ligand that is bonded to the Linker, namely, Z 1 is formed from reacting a functional group of the Targeting Ligand with the Linker.
- p1 is 1 and Z 1 is (CH 2 ) j C(O)NH.
- p1 is 1 and Z 1 is (CH 2 )C(O)NH.
- p1 is 1 and Z 1 is (CH 2 ) 2 C(O)NH.
- p1 is 1 and Z 1 is (CH 2 ) 3 C(O)NH.
- p1 is 1
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 1.
- p1 is 1
- Z 1 is (CH 2 )C(O)NH
- p3 is 1.
- p1 is 1
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 1.
- p1 is 1
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 1
- p2 is 0.
- p1 is 1
- Z 1 is (CH 2 )C(O)NH
- p3 is 1
- p2 is 0.
- p1 is 1
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 1
- p2 is 0.
- p1 is 1, Z1 is (CH2)jC(O)NH, p3 is 1, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 1, p2 is 0, and each W is O.
- p1 is 1, Z1 is (CH2)2C(O)NH, p3 is 1, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH2)2C(O)NH, p3 is 1, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 1, p2 is 0, and each W is CH 2 .
- p1 is 1, Z1 is (CH2)C(O)NH, p3 is 1, p2 is 0, and each W is CH2.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 1, p2 is 0, and each W is CH 2 .
- p1 is 2 and Z 1 is (CH 2 )C(O)NH.
- p1 is 2 and Z 1 is (CH 2 ) 2 C(O)NH.
- p1 is 2 and Z 1 is (CH 2 ) 3 C(O)NH.
- p1 is 2
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 2.
- p1 is 2, Z 1 is (C (O)NH, and p3 is 2.
- p1 is 2, Z 1 is (CH 2 ) 2 C(O)NH, and p3 is 2.
- p1 is 2
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 2
- Z 1 is (CH 2 )C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 2
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 2, Z1 is (CH2)jC(O)NH, p3 is 2, p2 is 0, and each W is O. (163) In one embodiment, p1 is 2, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O. (164) In one embodiment, p1 is 2, Z1 is (CH2)2C(O)NH, p3 is 2, p2 is 0, and each W is O. (165) In one embodiment, p1 is 2, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 2, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 2, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 3 and Z 1 is (CH 2 )C(O)NH.
- p1 is 3 and Z 1 is (CH 2 ) 2 C(O)NH.
- p1 is 3 and Z 1 is (CH 2 ) 3 C(O)NH.
- p1 is 3
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 3.
- p1 is 3
- Z 1 is (CH 2 )C(O)NH
- p3 is 3.
- p1 is 3
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 3.
- p1 is 3
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 3
- p2 is 1.
- p1 is 3
- Z 1 is (CH 2 )C(O)NH
- p3 is 3
- p2 is 1.
- p1 is 3
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 3
- p2 is 1.
- p1 is 3, Z 1 is (CH 2 ) j C(O)NH, p3 is 3, p2 is 1, and each W is O.
- p1 is 3, Z 1 is (CH 2 )C(O)NH, p3 is 3, p2 is 1, and each W is O.
- p1 is 3, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 3, p2 is 1, and each W is O.
- p1 is 3, Z 1 is (CH 2 ) j C(O)NH, p3 is 3, p2 is 1, and each W is CH 2 .
- p1 is 3, Z1 is (CH2)C(O)NH, p3 is 3, p2 is 1, and each W is CH2.
- p1 is 3, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 3, p2 is 1, and each W is CH 2 .
- p1 is 2, Z1 is (CH2)jC(O)NH, and p3 is 1.
- p1 is 2
- Z 1 is (CH 2 )C(O)NH
- p3 is 1.
- p1 is 2
- Z1 is (CH2)2C(O)NH
- p3 is 1.
- p1 is 2
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 1
- p2 is 1.
- p1 is 2
- Z 1 is (CH 2 )C(O)NH
- p3 is 1
- p2 is 1.
- p1 is 2
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 1
- p2 is 1.
- p1 is 2, Z 1 is (CH 2 ) j C(O)NH, p3 is 1, p2 is 1, and each W is O.
- p1 is 2, Z 1 is (CH 2 )C(O)NH, p3 is 1, p2 is 1, and each W is O. (191)
- p1 is 2, Z 1 is (C C(O)NH, p3 is 1, p2 is 1, and each W is O. (192)
- p1 is 2, Z 1 is (CH 2 ) j C(O)NH, p3 is 1, p2 is 1, and each W is CH 2 .
- p1 is 2, Z 1 is (CH 2 )C(O)NH, p3 is 1, p2 is 1, and each W is CH 2 . (194) In one embodiment, p1 is 2, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 1, p2 is 1, and each W is CH 2 . (195) In one embodiment, p1 is 1, Z 1 is (CH 2 ) j C(O)NH, and p3 is 2.
- p1 is 1, Z1 is (CH2)C(O)NH, and p3 is 2.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, and p3 is 2.
- p1 is 1, Z1 is (CH2)jC(O)NH, p3 is 2, and p2 is 0.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 2, and p2 is 0.
- p1 is 1
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, and p3 is 3.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, and p3 is 3.
- p1 is 1
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 3.
- p1 is 1
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 3
- p2 is 0.
- p1 is 1
- Z 1 is (CH 2 )C(O)NH
- p3 is 3
- p2 is 0.
- p1 is 1
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 3
- p2 is 0.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 3, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 3, p2 is 0, and each W is O.
- p1 is 1, Z1 is (CH2)2C(O)NH, p3 is 3, p2 is 0, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 3, p2 is 0, and each W is CH 2 .
- p1 is 1, Z1 is (CH2)C(O)NH, p3 is 3, p2 is 0, and each W is CH2.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 3, p2 is 0, and each W is CH 2 .
- p1 is 4 and Z1 is (CH2)C(O)NH.
- p1 is 4 and Z 1 is (CH 2 ) 2 C(O)NH.
- p1 is 4 and Z 1 is (CH 2 ) 3 C(O)NH.
- p1 is 4
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 2.
- p1 is 4
- Z 1 is (CH 2 )C(O)NH
- p3 is 2.
- p1 is 4
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2.
- p1 is 4, Z 1 is (C (O)NH, p3 is 2, and p2 is 0.
- p1 is 4, Z 1 is (CH 2 )C(O)NH, p3 is 2, and p2 is 0.
- p1 is 4
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 4, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 4, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 4, Z1 is (CH2)2C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 4, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 4, Z1 is (CH2)C(O)NH, p3 is 2, p2 is 0, and each W is CH2.
- p1 is 4, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 3, Z 1 is (CH 2 ) j C(O)NH, and p3 is 2.
- p1 is 3
- Z 1 is (CH 2 )C(O)NH
- p3 is 2.
- p1 is 3
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2.
- p1 is 3
- Z 1 is (CH 2 ) j C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 3
- Z 1 is (CH 2 )C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 3
- Z 1 is (CH 2 ) 2 C(O)NH
- p3 is 2
- p2 is 0.
- p1 is 3, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 3, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 3, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 3, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 3, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 3, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, and p3 is 2.
- p1 is 1, Z 1 is (CH 2 )C(O)NH, and p3 is 2.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, and p3 is 2.
- p1 is 1
- Z1 is (CH2)jC(O)NH
- p3 is 2
- p2 is 1.
- p1 is 1
- Z 1 is (CH 2 )C(O)NH
- p3 is 2
- p2 is 1.
- p1 is 1
- Z1 is (CH2)2C(O)NH
- p3 is 2
- p2 is 1.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 1, and each W is O.
- p1 is 1, Z1 is (CH2)C(O)NH, p3 is 2, p2 is 1, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 1, and each W is O.
- p1 is 1, Z 1 is (CH 2 ) j C(O)NH, p3 is 2, p2 is 1, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 )C(O)NH, p3 is 2, p2 is 1, and each W is CH 2 .
- p1 is 1, Z 1 is (CH 2 ) 2 C(O)NH, p3 is 2, p2 is 1, and each W is CH 2 .
- p1 is 3, Z 1 is O(CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 3, Z 1 is O(CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 2, Z 1 is O(CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1 is 2, Z 1 is O(CH 2 )C(O)NH, p3 is 2, p2 is 0, and each W is CH2.
- p1 is 1, Z 1 is O(CH 2 )C(O)NH, p3 is 3, p2 is 0, and each W is O.
- p1 is 1, Z1 is O(CH2)C(O)NH, p3 is 3, p2 is 0, and each W is CH 2 .
- p1 is 2
- Z 1 is (CH 2 )N(CH 3 )CH 2 C(O)NH
- p3 is 2
- p2 is 0, and each W is CH 2 .
- p1 is 2
- Z 1 is (CH 2 )N(CH 3 )CH 2 C(O)NH
- p3 is 2
- p2 is 0, and each W is O.
- p1 is 2, Z 1 is C(O)NH, p3 is 2, p2 is 0, and each W is CH 2 .
- p1 is 2, Z 1 is C(O)NH, p3 is 2, p2 is 0, and each W is O.
- p1, Z 1 , p3, p2, and W are each as defined, where applicable, in any one of (1)-(267), and Q is absent.
- p1, Z 1 , p3, p2, and W are each as defined, where applicable, in any one of (1)-(267), and Q is NHC(O)CH 2 .
- p1, Z 1 , p3, p2, and W are each as defined, where applicable, in any one of (1)-(267), and Q is O(CH 2 ) 1-2 .
- p1, Z 1 , p3, p2, and W are each as defined, where applicable, in any one of (1)-(267), and Q is O(CH 2 ).
- p1, Z 1 , p3, p2, and W are each as defined, where applicable, in any one of (1)-(267), and Q is O(CH2CH2).
- the Linker–Targeting Ligand has the structure selected from Table L:
- Z 1 , W, Q, TL, p1, p3, and j are each as described above.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L1a– L1k and L1m– L1y. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D1, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D1, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D1, and the Linker is L1a, L1b, or L1c. In one embodiment, the Degron is of Formula D1, and the Linker is L1d, L1e, or L1f. In one embodiment, the Degron is of Formula D1, and the Linker is L1g or L1h. In one embodiment, the Degron is of Formula D1, and the Linker is L1i, L1j, or L1k.
- the Degron is of Formula D1, and the Linker is L1m or L1n. In one embodiment, the Degron is of Formula D1, and the Linker is L1o-L1u. In one embodiment, the Degron is of Formula D1, and the Linker is L1o or L1p. In one embodiment, the Degron is of Formula D1, and the Linker is L1p or L1q. In one embodiment, the Degron is of Formula D1, and the Linker is L1r or L1s. In one embodiment, the Degron is of Formula D1, and the Linker is L1t or L1u. In one embodiment, the Degron is of Formula D1, and the Linker is L1v-L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L1a– L1k and L1m– L1y.
- DL Degron-Linker
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L1a– L1k and L1m– L1u.
- DL Degron-Linker
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L1a– L1k and L1m– L1u.
- the Degron is of Formula D1a, D1b, D1c, D 1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1a, L1b, or L1c.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1d, L1e, or L1f.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1g or L1h.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1i, L1j, or L1k.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1m or L1n.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1o-L1u.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1o or L1p.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1p or L1q.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1r or L1s.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1t or L1u.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is L1v-L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L1a– L1k and L1m– L1y. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D2, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D2, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D2, and the Linker is L1a, L1b, or L1c. In one embodiment, the Degron is of Formula D2, and the Linker is L1d, L1e, or L1f. In one embodiment, the Degron is of Formula D2, and the Linker is L1g or L1h. In one embodiment, the Degron is of Formula D2, and the Linker is L1i, L1j, or L1k.
- the Degron is of Formula D2, and the Linker is L1m or L1n. In one embodiment, the Degron is of Formula D2, and the Linker is L1o-L1u. In one embodiment, the Degron is of Formula D2, and the Linker is L1o or L1p. In one embodiment, the Degron is of Formula D2, and the Linker is L1p or L In one embodiment, the Degron is of Formula D2, and the Linker is L1r or L1s. In one embodiment, the Degron is of Formula D2, and the Linker is L1t or L1u. In one embodiment, the Degron is of Formula D2, and the Linker is L1v-L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k and L1m– L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k and L1m– L1u.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1a, L1b, or L1c. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1d, L1e, or L1f. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D2a
- the Degron is of Formula D2a or D2b, and the Linker is L1g or L1h. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1i, L1j, or L1k. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1m or L1n. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1o-L1u. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1o or L1p.
- the Degron is of Formula D2a or D2b, and the Linker is L1p or L1q. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1r or L1s. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1t or L1u. In one embodiment, the Degron is of Formula D2a or D2b, and the Linker is L1v-L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L1a– L1k and L1m– L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L1a– L1k and L1m– L1u.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D2c or D2d, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1a, L1b, or L1c. In one embodiment, the Degron is of Formula D2c or D2d, and t nker is L1d, L1e, or L1f.
- the Degron is of Formula D2c or D2d, and the Linker is L1g or L1h. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1i, L1j, or L1k. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1m or L1n. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1o-L1u. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1o or L1p.
- the Degron is of Formula D2c or D2d, and the Linker is L1p or L1q. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1r or L1s. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1t or L1u. In one embodiment, the Degron is of Formula D2c or D2d, and the Linker is L1v-L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L1a– L1k and L1m– L1y.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L1a– L1k and L1m– L1u.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L1a– L1k, L1m, and L1n.
- the Degron is of Formula D2e or D2f, and the Linker is selected from L1a– L1k and L1m– L1u. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is selected from L1a– L1k, L1m, and L1n. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1a, L1b, or L1c. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1d, L1e, or L1f. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1g or L1h.
- the Degron is of Formula D2e or D2f, and the Linker is L1i, L1j, or L1k. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1m or L1n. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1o-L1u. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1o or L1p. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1p or L1q.
- the Degron is of Formula D2e or D2f, and the Linker is L1r or L1s. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1t or L1u. In one embodiment, the Degron is of Formula D2e or D2f, and the Linker is L1v-L1y.
- the Linker is of Formula L2:
- Z 2 is absent, C(O), CH 2 , O(CH 2 ) j1 C(O), or NR 20 (CH 2 ) j1 C(O);
- R 20 is H or C 1 -C 3 alkyl
- j 1 is 1, 2, or 3;
- Q2 is absent, NHC(O)CH2, or C(O)(CH2)1-4; wherein the Linker is covalently bonded to a Degron via the next to Q 2 , and covalently bonded to a Targeting Ligand via the next to Z 2 .
- s3 is 0.
- s3 is 1.
- Z 2 is absent.
- Z 2 is CH 2 .
- Z 2 is C(O).
- Z 2 is O(CH 2 ) j1 C(O). In one embodiment, Z 2 is O(CH 2 )C(O). In one embodiment, Z is NR 20 (CH 2 ) j1 C(O).
- Z 2 is NR 20 (CH 2 ) j1 C(O); and R 20 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 2 is NR 20 (CH 2 ) j1 C(O); and R 20 is H.
- Z 2 is NR 20 (CH 2 ) j1 C(O); R 20 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j 1 is 1.
- Z 2 is NR 20 (CH 2 ) j1 C(O); R 20 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j 1 is 2.
- Z2 is NR20(CH2)j1C(O); R20 is C1-C3 alkyl selected from methyl, ethyl, and propyl; and j 1 is 3.
- Z2 is NR20(CH2)j1C(O); R20 is H; and j1 is 1.
- Z 2 is NR 20 (CH 2 ) j1 C(O); R 20 is H; and j 1 is 2.
- Z 2 is NR 20 (CH 2 ) j1 C(O); R 20 is H; and j 1 is 3.
- Q 2 is absent.
- Q 2 is C(O)(CH 2 ) 1-4 .
- Q 2 is NHC(O)CH 2 .
- s3 is 0 and Q 2 is absent.
- s3 is 0 and Q 2 is C(O)(CH 2 ) 1-4 . In one embodiment, s3 is 0 and Q 2 is NHC(O)CH 2 .
- s3 is 1 and Q 2 is absent.
- s3 is 1 and Q 2 is C(O)(CH 2 ) 1-4 .
- s3 is 1 and Q 2 is NHC(O)CH 2 .
- Q2 is absent and Z is absent.
- Q 2 is absent and Z is CH 2 .
- Q2 is absent and Z is C(O).
- Q 2 is absent and Z is O(CH 2 ) j1 C(O).
- Q 2 is absent and Z is NR 20 (CH 2 ) j1 C(O).
- Q 2 is C(O)(CH 2 ) 1-4 and Z is absent.
- Q 2 is C(O)(CH 2 ) 1-4 and Z is CH 2 .
- Q 2 is C(O)(CH 2 ) 1-4 and Z is C(O).
- Q 2 is C(O)(CH 2 ) 1-4 and Z is O(CH 2 ) j1 C(O).
- Q 2 is C(O)(CH 2 ) 1-4 and Z is NR 20 (CH 2 ) j1 C(O).
- Q 2 is NHC(O)CH 2 and Z is absent.
- Q 2 is NHC(O)CH 2 and Z is CH 2 .
- Q 2 is NHC(O)CH 2 and Z is C(O).
- Q 2 is NHC(O)CH 2 and Z is O(CH 2 ) j1 C(O).
- Q 2 is NHC(O)CH 2 and Z is NR 20 (CH 2 ) j1 C(O).
- s3 is 0 and Z 2 is absent.
- s3 is 1 and Z 2 is absent.
- s3 is 0 and Z 2 is CH 2 .
- s3 is 1 and Z 2 is CH 2 .
- s3 is 0 and Z2 is C(O).
- s3 is 1 and Z 2 is C(O).
- s3 is 0 and Z2 is NR20(CH2)j1C(O).
- s3 is 1 and Z 2 is NR 20 (CH 2 ) j1 C(O).
- the Linker–Targeting Ligand (TL) has the structure selected from Table M:
- any one of the Degrons described herein can be covalently bound to any one of the Linkers described herein.
- Any one of the Targeting Ligands described herein can be covalently bound to any one of the Linkers described herein.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2a– L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2a. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2b or L2c. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2d or L2e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2f. In one embodiment, the present application provide Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2b -L2d. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L2d or L2f.
- DL Degron-Linker
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2a– L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2a.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2b or L2c.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2d or L2e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2b -L2d.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L2d or L2f.
- DL Degron-Linker
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2a– L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2a. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2b or L2c. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2d or L2e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2b -L2d. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L2d or L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2a– L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2a. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2b or L2c. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2d or L2e. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2f.
- DL Degron-Linker
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2b -L2d. In one embodiment, the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L2d or L2f.
- DL Degron-Linker
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2a– L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2a. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2b or L2c.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2d or L2e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2b -L2d.
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L2d or L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2a– L2f. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2a. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from or L2c.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2d or L2e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2f.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2b -L2d.
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L2d or L2f.
- the Linker is of Formula L3:
- Z 3 is absent, C(O), CH 2 , NR 21 (CH 2 ) j2 , O(CH 2 ) j2 C(O), O(CH 2 ) j2 C(O)NR 21 , C(O)NR 21 ,
- each R 21 is independently H or C 1 -C 3 alkyl
- j2 is 1, 2, or 3;
- Q 3 is absent, (CH 2 ) 1-3 , (CH 2 ) 1-3 NH, or NHC(O)CH 2 ; wherein the Linker is covalently bonded to the Degron via the next to Q 3 , and covalently bonded to the Targeting Ligand via the next to Z 3 .
- Z 3 is absent.
- Z 3 is C(O).
- Z 3 is CH 2 .
- Z 3 is NR 21 (CH 2 ) j2 .
- Z 3 is NR 21 (CH 2 ) j21 ; and R 21 is H.
- Z 3 is NR 21 (CH 2 ) j2 ; and R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 3 is NR 21 (CH 2 ) j2 ; and j2 is 1.
- Z 3 is NR 21 (CH 2 ) j2 ; R 21 is H; and j2 is 1.
- Z 3 is NR 21 (CH 2 ) j2 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 1.
- Z 3 is NR 21 (CH 2 ) j2 ; and j2 is 2.
- Z 3 is NR 21 (CH 2 ) j2 ; R 21 is H; and j2 is 2. In one embodiment, Z 3 is NR 21 (CH 2 ) j2 ; R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 2.
- Z 3 is NR 21 (CH 2 ) j2 ; and j2 is 3.
- Z 3 is NR 21 (CH 2 ) j2 ; R 21 is H; and j2 is 3.
- Z3 is NR21(CH2)j2; R21 is C1-C3 alkyl selected from methyl, ethyl, and propyl; and j2 is 3.
- Z3 is O(CH2)j2C(O).
- Z 3 is O(CH 2 ) j2 C(O) ; and j2 is 1.
- Z 3 is O(CH 2 ) j2 C(O) ; and j2 is 2.
- Z 3 is O(CH 2 ) j2 C(O) ; and j2 is 3.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 .
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; and R 21 is H.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; and R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; and j2 is 1.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; R 21 is H; and j2 is 1.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 1.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; and j2 is 2.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; R 21 is H; and j2 is 2.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 2.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ; and j2 is 3.
- Z3 is O(CH2)j2C(O)NR21; R21 is H; and j2 is 3.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 3.
- Z 3 is C(O)NR 21 .
- Z3 is C(O)NR21; and R21 is H.
- Z 3 is C(O)NR 21 ; and R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl.
- Z 3 is (CH 2 ) j2 C(O)NR 21 .
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; and R 21 is H.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; and R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl. In one embodiment, Z 3 is (CH 2 ) j2 C(O)NR 21 ; and j2 is 1.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; R 21 is H; and j2 is 1.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 1.
- Z3 is (CH2)j2C(O)NR21; and j2 is 2.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; R 21 is H; and j2 is 2.
- Z3 is (CH2)j2C(O)NR21; R21 is C1-C3 alkyl selected from methyl, ethyl, and propyl; and j2 is 2.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; and j2 is 3.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ; R 21 is H; and j2 is 3.
- Z 3 is (CH 2 ) j2 C(O)NR 21 ;
- R 21 is C 1 -C 3 alkyl selected from methyl, ethyl, and propyl; and j2 is 3.
- Z 3 is absent and Q 3 is absent.
- Z 3 is C(O) and Q 3 is absent.
- Z 3 is CH 2 and Q 3 is absent.
- Z 3 is NR 21 (CH 2 ) j2 and Q 3 is absent.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 and Q 3 is absent.
- Z 3 is O(CH 2 ) j2 C(O) and Q 3 is absent.
- Z 3 is C(O)NR 21 and Q 3 is absent.
- Z 3 is (CH 2 ) j2 C(O)NR 21 and Q 3 is absent.
- Z 3 is absent and Q 3 is (CH 2 ) 1-3 .
- Z 3 is C(O) and Q 3 is (CH 2 ) 1-3 .
- Z 3 is CH 2 and Q 3 is (CH 2 ) 1-3 .
- Z3 is NR21(CH2)j2 and Q3 is (CH2)1-3.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 and Q 3 is (CH 2 ) 1-3 .
- Z3 is O(CH2)j2C(O) and Q3 is (CH2)1-3.
- Z 3 is C(O)NR 21 and Q 3 is (CH 2 ) 1-3 .
- Z3 is (CH2)j2C(O)NR21 and Q3 is (CH2)1-3.
- Z 3 is absent and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is C(O) and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is CH 2 and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is NR 21 (CH 2 ) j2 and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is O(CH 2 ) j2 C(O)NR 21 and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is O(CH 2 ) j2 C nd Q 3 is (CH 2 ) 1-3 NH. In one embodiment, Z 3 is C(O)NR 21 and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is (CH 2 ) j2 C(O)NR 21 and Q 3 is (CH 2 ) 1-3 NH.
- Z 3 is absent and Q 3 is NHC(O)CH 2 .
- Z 3 is C(O) and Q 3 is NHC(O)CH 2 .
- Z3 is CH2 and Q3 is a NHC(O)CH2.
- Z 3 is NR 21 (CH 2 ) j2 and Q 3 is NHC(O)CH 2 .
- Z3 is O(CH2)j2C(O)NR21 and Q3 is NHC(O)CH2.
- Z 3 is O(CH 2 ) j2 C(O) and Q 3 is NHC(O)CH 2 .
- Z 3 is C(O)NR 21 and Q 3 is a NHC(O)CH 2 .
- Z 3 is (CH 2 ) j2 C(O)NR 21 and Q 3 is NHC(O)CH 2 .
- the Linker–Targeting Ligand has the structure selected from Table N:
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3a– L3v. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3a-L3k. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3m-L3v. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3a-L3e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3f-L3j. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3k–L3p. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1, and the Linker is selected from L3q- L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3a– L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3a- L3k.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3m-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3a-L3e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3f-L3j.
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3k–L3p.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l, and the Linker is selected from L3q-L3v.
- the Degron is of Formula D1a, D1b, D1c, D1d, D1e, D1f, D1g, D1h, D1i, D1j, D1k, or D1l
- the Linker is selected from L3q-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3a– L3v. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3a-L3k. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3m-L3v. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3a-L3e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3f-L3j. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3k–L3p. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2, and the Linker is selected from L3q-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3a– L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3a-L3k.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3m-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3a-L3e. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3f-L3j. In one embodiment, the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3k–L3p. In one embodiment, the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2a or D2b, and the Linker is selected from L3q- L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3a– L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the L r is selected from L3a-L3k.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3m-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3a-L3e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3f-L3j.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3k–L3p.
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2c or D2d, and the Linker is selected from L3q- L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3a– L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3a-L3k.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3m-L3v.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3a-L3e.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3f-L3j.
- the present application provides the Degron-Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3k–L3p.
- the present application provides the Degron- Linker (DL), wherein the Degron is of Formula D2e or D2f, and the Linker is selected from L3q- L3v.
- the Linker is designed and optimized based on SAR (structure- activity relationship) and X-ray crystallography of the Targeting Ligand with regard to the location of attachment for the Linker.
- the optimal Linker length and composition vary by the Targeting Ligand and can be estimated based upon X-ray structure of the Targeting Ligand bound to its target.
- Linker length and composition can be also modified to modulate metabolic stability and pharmacokinetic (PK) and pharmacodynamics (PD) parameters.
- Some embodiments of present application relate to the Degron-Linkers (DL) having one of the following structures in Table B:
- Some of the foregoing compounds can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, such as stereoisomers and/or diastereomers.
- compounds of the application may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
- the compounds of the application are enantiopure compounds.
- mixtures of stereoisomers or diastereomers are provided.
- certain compounds, as described herein, may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated.
- the application additionally encompasses the compounds as individual Z/E isomers substantially free of other E/Z isomers and alternatively, as mixtures of various isomers.
- the present application provides compounds that target proteins, such as BRD9 for degradation, which have numerous advantages, such as protein activity, over inhibitors of protein function and can a) overcome resistance in certain cases; b) prolong the kinetics of drug effect by destroying the protein, thus requiring resynthesis of the protein even after the compound has been metabolized; c) target all functions of a protein at once rather than a specific catalytic activity or binding event; d) expand the number of drug targets by including all proteins that a ligand can be developed for, rather than proteins whose activity can be affected by a small molecule inhibitor, antagonist or agonist; and e) have increased potency compared to inhibitors due to the possibility of the small molecule acting catalytically.
- target proteins such as BRD9 for degradation
- Some embodiments of the present application relate to degradation or loss of 30% to 100% of the target protein. Some embodiments relate to the loss of 50-100% of the target protein. Other embodiments relate to the loss of 75-95% of the targeted protein.
- a bifunctional compound of the present application (e.g., a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is capable of modulating (e.g., decreasing) the amount of a targeted protein (e.g., BRD9).
- a bifunctional compound of the present application (e.g., a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein) is also capable of degrading a targeted protein (e.g., BRD9) through the UPP pathway.
- a bifunctional compound of the present application is capable of treating or preventing a disease or disorder in which BRD9 plays a role.
- a bifunctional compound of the present application e.g., a bifunctional compound of any of the ulae described herein, or selected from any bifunctional compounds described herein
- Modulation of BRD9 through UPP-mediated degradation by a bifunctional compound of the application, such as those described herein, provides a novel approach to the treatment, prevention, or amelioration of diseases or disorders in which BRD9 plays a role including, but not limited to, cancer and metastasis, inflammation, arthritis, systemic lupus
- BRD9 erthematosus
- skin-related disorders pulmonary disorders
- cardiovascular disease ischemia
- neurodegenerative disorders liver disease
- gastrointestinal disorders viral and bacterial infections
- central nervous system disorders Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinal cord injury, and peripheral neuropathy.
- modulation of BRD9 through UPP-mediated degradation by a bifunctional compound of the application, such as those described herein also provides a new paradigm for treating, preventing, or ameliorating diseases or disorders in which BRD9 is deregulated.
- a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein of the present application is more efficacious in treating a disease or condition or is more capable of treating a disease or condition resistant to the Targeting Ligand than when the Targeting Ligand is administered alone or not bonded to a Linker and a Degron.
- the disease of condition is cancer.
- a bifunctional compound of any of the formulae described herein, or selected from any bifunctional compounds described herein of the present application is capable of modulating or decreasing the amount of BRD9, and thus is useful in treating a disease or condition in which BRD9 plays a role.
- the disease or condition is cancer.
- the bifunctional compound of the present application that is more efficacious in treating a disease or condition or is more capable of treating a disease or condition resistant to the Targeting Ligand than when the Targeting Ligand is administered alone or not bonded to a Linker and a Degron is more potent in inhibiting the growth of cells or decreasing the viability of cells than the Targeting Ligand when the Targeting Ligand is administered alone or not bonded to a Linker and a Degron.
- the cells are cancer cells.
- the bifunctional compound inhibits the growth of cells or decreases the viability of cells at an IC 50 that is lower than the IC 50 of the Targeting Ligand when the Targeting Ligand is admin d alone or not bonded to a Linker and a Degron for inhibiting the growth or decreasing the viability of the cells.
- the cells are cancer cells.
- the IC 50 of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand.
- the IC50 of the bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand. In one embodiment, the IC50 of the bifunctional compound is at most 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand.
- the IC 50 of the bifunctional compound is at most 10%, 8%, 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand. In one embodiment, the IC 50 of the bifunctional compound is at most 5%, 4%, 3%, 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand. In one embodiment, the IC 50 of the bifunctional compound is at most 2%, 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand.
- the IC 50 of the bifunctional compound is at most 1%, 0.8%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the IC 50 of the Targeting Ligand.
- the bifunctional compound inhibits the growth of cells or decreases the viability of cells at an E max that is lower than the E max of the Targeting Ligand when the Targeting Ligand is administered alone or not bonded to a Linker and a Degron for inhibiting the growth or decreasing the viability of the cells.
- the cells are cancer cells.
- the E max of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the E max of the Targeting Ligand. In one embodiment, the E max of the bifunctional compound is at most 50%, 40%, 30%, 20%, 10%, 8%, 5%, 4%, 3%, 2%, or 1% of the Emax of the Targeting Ligand. In one embodiment, the Emax of the bifunctional compound is at most 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the E max of the Targeting Ligand.
- the inhibition of BRD9 activity is measured by IC 50 .
- the inhibition of BRD9 activity is measured by EC50.
- Potency of the inhibitor can be determined by EC 50 value.
- a compound with a lower EC 50 value, as determined under substantially similar conditions is a more potent inhibitor relative to a compound with a higher EC 50 value.
- the substantially similar conditions comprise determining a BRD9-dependent cell proliferation in vitro or in vivo in cells expressing BRD9. Potency of the inhibitor can also be determined by IC 50 value.
- a compound with a lower IC 50 value, as determined under substantially similar conditions is a more potent inhibitor relative to a compound with a higher IC 50 value.
- the substantially similar conditions comprise determining a BRD9-dependent cell proliferation, in vitro or in vivo in cells expressing BRD9.
- the bifunctional compounds of the present application are useful as anticancer agents, and thus may be useful in the treatment of cancer, by effecting tumor cell death or inhibiting the growth of tumor cells.
- the disclosed anticancer agents are useful in the treatment of cancers and other proliferative disorders, including, but not limited to breast cancer, cervical cancer, colon and rectal cancer, leukemia, lung cancer, non-small cell lung cancer, melanoma, multiple myeloma, non- Hodgkin's lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, gastric cancer, leukemias, including but not limited to myeloid, lymphocytic, myelocytic and lymphoblastic leukemias, malignant melanomas, and T-cell lymphoma.
- A“selective BRD9 inhibitor,” can be identified, for example, by comparing the ability of a compound to inhibit BRD9 protein activity to its ability to inhibit other bromodomain proteins. For example, a substance may be assayed for its ability to inhibit BRD9 protein activity, as well as BRD1, BRD4, and/or BRD7, and/or other bromodomains. In some embodiments, the selectivity can be identified by measuring the EC 50 or IC 50 of the compounds. Definitions
- alkyl refers to saturated, straight or branched-chain hydrocarbon radicals containing, in certain embodiments, between one and six carbon atoms.
- C1-C3 alkyl includes methyl, ethyl, n-propyl, and isopropyl.
- C1-C6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert- butyl, neopentyl, and n-hexyl radicals.
- alkoxy refers to an -O-alkyl radical.
- C 1 -C 3 alkoxy includes methoxy, ethoxy, n-propoxy, and isopropoxy.
- Examples of C 1 -C 6 alkyl radicals include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy, and n-hexoxy radicals.
- hal halo
- halogen refer to an atom selected from fluorine, chlorine, bromine and iodine.
- aryl refers to a mono- or poly-cyclic carbocyclic ring system having one or more aromatic rings, fused or non-fused, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like.
- aralkyl refers to an alkyl residue attached to an aryl ring. Examples include, but are not limited to, benzyl, phenethyl and the like.
- cycloalkyl denotes a monovalent group derived from a monocyclic or polycyclic saturated or partially unsaturated carbocyclic ring compound.
- C 3 -C 8 cycloalkyl examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl; and examples of C 3 -C 12 -cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.
- a monovalent group derived from a monocyclic or polycyclic carbocyclic ring compound having at least one carbon-carbon double bond by the removal of a single hydrogen atom examples include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like.
- heteroaryl refers to a mono- or poly-cyclic (e.g., bi-, or tri- cyclic or more) fused or non-fused, radical or ring system having at least one aromatic ring, having from five to ten ring atoms of which one ring atoms is selected from S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon.
- mono- or poly-cyclic e.g., bi-, or tri- cyclic or more fused or non-fused, radical or ring system having at least one aromatic ring, having from five to ten ring atoms of which one ring atoms is selected from S, O, and N; zero, one, or two ring atoms are additional heteroatoms independently selected from S, O, and N; and the remaining ring atoms are carbon.
- Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, and the like.
- heteroarylkyl refers to an alkyl residue attached to a heteroaryl ring. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
- heterocyclyl refers to a non- aromatic 3-, 4-, 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused of non-fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, and (iv) the nitr heteroatom may optionally be quaternized.
- heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
- alkylamino refers to a group having the structure -NH(C 1 -C 12 alkyl), e.g., - NH(C1-C6 alkyl), where C1-C12 alkyl is as previously defined.
- dialkylamino refers to a group having the structure -N(C 1 -C 12 alkyl) 2 , e.g., -NH(C1-C6 alkyl), where C1-C12 alkyl is as previously defined.
- acyl includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids.
- Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates.
- Examples of aliphatic carbonyls include, but are not limited to, acetyl, propionyl, 2-fluoroacetyl, butyryl, 2-hydroxy acetyl, and the like.
- any of the aryls, substituted aryls, heteroaryls and substituted heteroaryls described herein, can be any aromatic group.
- Aromatic groups can be substituted or unsubstituted.
- hal refers to an atom selected from fluorine, chlorine, bromine and iodine.
- compounds of the application may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the application.
- substituents such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the application.
- phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.”
- substituted refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
- an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- substituent may be either the same or different at every position.
- -NHC(NH)-heteroaryl -NHC(NH)-heterocy kyl, -C(NH)NH-C 1 -C 12 -alkyl, -C(NH)NH-C 2 -C 12 -alkenyl, -C(NH)NH-C 2 -C 12 -alkenyl, C(NH)NH-C 3 -C 12 -cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NHheterocycloalkyl,
- cancer includes, but is not limited to, the following cancers: epidermoid Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma (squamous cell or epidermoid, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
- Gastrointestinal esophagus (squamous cell carcinoma, larynx, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel or small intestines (adenocarcinoma, lymphoma, carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel or large intestines (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colon, colon-rectum, colorectal, rectum; Genitourinary tract: kidney (
- uterus endometrial carcinoma
- cervix cervical carcinoma, pre-tumor cervical dysplasia
- ovaries ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma,
- adenocarcinoma, fibrosarcoma, melanoma), vagina clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Hematologic: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma) hairy cell; lymphoid disorders; Skin: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psorias
- BBD9 refers to bromodomain-containing protein 9.
- subject refers to a mammal.
- a subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like.
- the subject is a human.
- the subject may be referred to herein as a patient.
- Treating refers to a method of alleviating or abating a disease and/or its attendant symptoms.
- “preventing” or“prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.
- target protein(s) is used interchangeably with“target protein(s)”, unless the context clearly dictates otherwise.
- a“targeted protein” is BRD9.
- the terms“disease(s)”,“disorder(s)”, and“condition(s)” are used interchangeably, unless the context clearly dictates otherwise.
- terapéuticaally effective amount of a bifunctional compound or pharmaceutical composition of the application means a sufficient amount of the bifunctional compound or pharmaceutical composition so as to decrease the symptoms of a disorder in a subject.
- a therapeutically effective amount of a bifunctional compound or pharmaceutical composition of this application will be at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present application will be decided by the attending physician within the scope of sound medical judgment.
- the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
- the term "pharmaceutically acceptable salt” refers to those salts of the compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are
- salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the application, or separately by reacting the free base or acid function with a suitable acid or base.
- salts include, but are not limited to, nontoxic acid addition salts: salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid.
- inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
- organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid.
- pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate,
- ethanesulfonate formate, fumarate, glucohe te, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
- alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
- ester refers to esters of the bifunctional compounds formed by the process of the present application which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
- Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
- esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
- prodrugs refers to those prodrugs of the bifunctional compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present application.
- Prodrug means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to afford any compound delineated by the formulae of the instant application.
- prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology, vol.4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
- compositions containing, and methods of treating disorders through administering, pharmaceutically acceptable prodrugs of bifunctional compounds of the application can be converted into prodrugs.
- Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two, three, or four amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the application.
- the amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline, homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and
- phosphoryloxymethyloxy carbonyls as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115.
- Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups.
- Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed.
- Prodrugs of this type are described in J. Med. Chem.1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides. All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
- the application also provides for a pharmaceutical composition
- a pharmaceutical composition comprising a therapeutically effective amount of a bifunctional compound of the application, or an enantiomer, diastereomer, stereoisomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the application provides a kit comprising a bifunctional compound capable of inhibiting BRD9 activity selected from one or more compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, optionally in combination with a second agent and instructions for use in treating cancer.
- a bifunctional compound capable of inhibiting BRD9 activity selected from one or more compounds disclosed herein, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, optionally in combination with a second agent and instructions for use in treating cancer.
- the application provides a method of synthesizing a bifunctional compound disclosed herein.
- inventions are a method of making a bifunctional compound of any of the formulae herein using any one, or combination of, reactions delineated herein.
- the method can include the use of one or more intermediates or chemical reagents delineated herein.
- Another aspect is an isotopically labeled bifunctional compound of any of the formulae delineated herein.
- Such compounds have one or more isotope atoms which may or may not be radioactive, including but not limited to 3 H, 2 H, 14 C, 13 C, 18 F, 35 S, 32 P, 125 I, and 131 I introduced into the bifunctional compound.
- isotope atoms which may or may not be radioactive, including but not limited to 3 H, 2 H, 14 C, 13 C, 18 F, 35 S, 32 P, 125 I, and 131 I introduced into the bifunctional compound.
- Such compounds are useful for drug metabolism studies and diagnostics, as well as therapeutic applications.
- a bifunctional compound of the application can be prepared as a pharmaceutically acceptable acid addition salt by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid.
- a pharmaceutically acceptable base addition salt of a bifunctional compound of the application can be prepared by reacting the free acid form of the bifunctional compound with a pharmaceutically acceptable inorganic or organic base.
- the salt forms of the bifunctional compounds of the application can be prepared using salts of the starting materials or intermediates.
- the free acid or free base forms of the bifunctional compounds of the application can be prepared from the corresponding base addition salt or acid addition salt from, respectively.
- a bifunctional compound of the application in an acid addition salt form can be converted to the corresponding free base by treating with a suitable base, including but not limited to ammonium hydroxide solution, sodium hydroxide.
- a bifunctional compound of the application in a base addition salt form can be converted to the corresponding free acid by treating with a suitable acid, including but not limited to hydrochloric acid.
- Prodrugs of the bifunctional compounds of the application can be prepared by methods known to those of ordinary skill in the art (e.g., for further details see Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol.4, p.1985).
- appropriate prodrugs can be prepared by reacting a non-derivatized bifunctional compound of the application with a suitable carbamylating agent, including but not limited to 1,1- acyloxyalkylcarbanochloridate, para-nitrophenyl carbonate.
- Hydrates of bifunctional compounds of the present application can be conveniently prepared by recrystallization from an
- aqueous/organic solvent mixture using organic solvents such as dioxin, tetrahydrofuran or methanol.
- Acids and bases useful in the methods herein are known in the art.
- Acid catalysts are any acidic chemical, which can be inorganic, including but not limited to hydrochloric, sulfuric, nitric acids, aluminum trichloride or organic, including but not limited to
- Acids are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.
- Bases are any basic chemical, which can be inorganic, including but not limited to sodium bicarbonate, potassium hydroxide or organic, including but not limited to triethylamine, pyridine. Bases are useful in either catalytic or stoichiometric amounts to facilitate chemical reactions.
- stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein, such as therapeutic or prophylactic administration, to a subject.
- any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence.
- R 14 at each occurrence is selected independently from the definition of R 14 .
- combinations of substituents and/or variables are permissible, but only if such combinations result in stable compounds within a designated atom’s normal valency.
- some of the compounds of this application have one or more double bonds, or one or more asymmetric centers.
- Such compounds can occur as racemates, racemic mixtures, single enantiomers, individual dia omers, diastereomeric mixtures, and cis- or trans- or E- or Z- double isomeric forms, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)- for amino acids.
- the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662353793P | 2016-06-23 | 2016-06-23 | |
US201662438758P | 2016-12-23 | 2016-12-23 | |
PCT/US2017/039004 WO2017223452A1 (fr) | 2016-06-23 | 2017-06-23 | Dégradation de la protéine contenant un bromodomaine 9 (brd9) par conjugaison d'inhibiteurs de brd9 avec un ligand de la ligase e3 et procédés d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3474900A1 true EP3474900A1 (fr) | 2019-05-01 |
EP3474900A4 EP3474900A4 (fr) | 2020-03-11 |
Family
ID=60784767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17816295.4A Withdrawn EP3474900A4 (fr) | 2016-06-23 | 2017-06-23 | Dégradation de la protéine contenant un bromodomaine 9 (brd9) par conjugaison d'inhibiteurs de brd9 avec un ligand de la ligase e3 et procédés d'utilisation |
Country Status (5)
Country | Link |
---|---|
US (1) | US11285218B2 (fr) |
EP (1) | EP3474900A4 (fr) |
AU (1) | AU2017281903B2 (fr) |
CA (1) | CA3025806C (fr) |
WO (1) | WO2017223452A1 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
WO2019152440A1 (fr) | 2018-01-30 | 2019-08-08 | Foghorn Therapeutics Inc. | Procédés et composés pour traiter des troubles |
MX2020010420A (es) * | 2018-04-04 | 2020-12-11 | Arvinas Operations Inc | Moduladores de la proteólisis y métodos asociados de uso. |
FI3784663T3 (fi) | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
WO2020007322A1 (fr) * | 2018-07-04 | 2020-01-09 | 清华大学 | Composé ciblé pour la dégradation d'une protéine bet et utilisation associée |
WO2020041331A1 (fr) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives |
US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
EP3846800A4 (fr) * | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Composés pour la dégradation de brd9 ou mth1 |
JP7168773B2 (ja) * | 2018-09-30 | 2022-11-09 | 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ | イソインドリン化合物、その調製方法、医薬組成物および使用 |
US11192900B2 (en) | 2018-10-30 | 2021-12-07 | Nuvation Bio Inc. | Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors |
EP3880669A1 (fr) | 2018-11-13 | 2021-09-22 | Biotheryx, Inc. | Isoindolinones substituées |
CN111285850B (zh) * | 2018-12-06 | 2022-04-22 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
CN109350616B (zh) * | 2018-12-18 | 2020-04-21 | 南华大学 | I-brd9或其衍生物在制备抗癫痫药物中的应用 |
EP3897631A4 (fr) * | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | Dégradation ciblée de protéines |
US20230066136A1 (en) | 2019-01-29 | 2023-03-02 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
WO2020160193A2 (fr) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Composés et leurs utilisations |
CN113874016A (zh) * | 2019-01-29 | 2021-12-31 | 福宏治疗公司 | 化合物及其用途 |
EP3917517A4 (fr) * | 2019-01-29 | 2023-01-25 | Foghorn Therapeutics Inc. | Composés et leurs utilisations |
WO2020160196A1 (fr) * | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Composés et leurs utilisations |
CA3133314A1 (fr) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Conjugues de vesicules extracellulaires et leurs utilisations |
US20220387906A1 (en) | 2019-03-21 | 2022-12-08 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2020253711A1 (fr) * | 2019-06-17 | 2020-12-24 | 中国科学院上海药物研究所 | Composé de pyrrolopyridone, procédé de préparation correspondant, composition et utilisation associées |
JP7465945B2 (ja) | 2019-07-02 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | Bet阻害剤としてのヘテロ環式化合物 |
JP2022540935A (ja) | 2019-07-17 | 2022-09-20 | アルビナス・オペレーションズ・インコーポレイテッド | タウタンパク質標的化化合物および関連する使用方法 |
WO2021022163A2 (fr) * | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Composés et leurs utilisations |
EP4031247A1 (fr) * | 2019-09-16 | 2022-07-27 | Novartis AG | Agents de dégradation bifonctionnels et leurs méthodes d'utilisation |
JOP20220069A1 (ar) * | 2019-09-16 | 2023-01-30 | Novartis Ag | عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها |
CA3154073A1 (fr) | 2019-12-20 | 2021-06-24 | Christopher G. Nasveschuk | Composes d'isoindolinone et d'indazole pour la degradation de l'egfr |
AU2021214767A1 (en) * | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
CA3165309A1 (fr) | 2020-03-05 | 2021-09-10 | Christopher G. Nasveschuk | Composes pour la degradation ciblee de la brd9 |
BR112022020392A2 (pt) * | 2020-04-08 | 2022-11-29 | Rumi Scient Holdings Inc | Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9 |
WO2021237100A1 (fr) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Procédés d'administration ciblée de vésicules extracellulaires dans le poumon |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2021257863A1 (fr) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2 |
TW202216713A (zh) | 2020-07-02 | 2022-05-01 | 美商英塞特公司 | 作為jak2 v617f抑制劑之三環脲化合物 |
WO2022006456A1 (fr) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2 |
CN116322780A (zh) * | 2020-07-29 | 2023-06-23 | 福宏治疗公司 | 化合物及其用途 |
US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
WO2022046989A1 (fr) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2 |
WO2022066928A2 (fr) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Procédé de préparation de vésicules extracellulaires |
WO2022140231A1 (fr) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Composés de déazaguanine utilisés en tant qu'inhibiteurs de v617f de jak2 |
WO2022152821A1 (fr) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Composés d'isoindolinone |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
IL305860A (en) | 2021-04-16 | 2023-11-01 | Arvinas Operations Inc | BCL6 proteolysis modulators and related methods of use |
WO2023283263A1 (fr) | 2021-07-06 | 2023-01-12 | Foghorn Therapeutics Inc. | Sel de citrate, compositions pharmaceutiques et leurs procédés de fabrication et d'utilisation |
WO2023039081A2 (fr) * | 2021-09-08 | 2023-03-16 | Memorial Sloan-Kettering Cancer Center | Protéines suppresseurs de tumeurs ink4 véhiculant la résistance à des inhibiteurs de kinase cdk4/6 |
WO2023039208A1 (fr) * | 2021-09-09 | 2023-03-16 | C4 Therapeutics, Inc. | Composés sélectionnés pour la dégradation ciblée de brd9 |
WO2023059792A1 (fr) * | 2021-10-06 | 2023-04-13 | C4 Thrapeutics, Inc. | Composés de dégradation de la protéine 3 non structurale de coronavirus |
TW202333695A (zh) * | 2022-01-27 | 2023-09-01 | 大陸商四川海思科製藥有限公司 | 含氮雜芳環化合物及其組合物和藥學上的應用 |
WO2023205701A1 (fr) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Hétérocycles macrocycliques et leurs utilisations |
CN115261469B (zh) * | 2022-06-23 | 2023-03-31 | 山东第一医科大学附属省立医院(山东省立医院) | Brd9在慢性淋巴细胞白血病诊治中的应用 |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024057021A1 (fr) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | Composés pour la dégradation ciblée d'une protéine |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011008260A2 (fr) * | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Peptides bifonctionnels insérés et leurs utilisations |
KR20120093220A (ko) | 2009-09-16 | 2012-08-22 | 아빌라 테라퓨틱스, 인크. | 단백질 키나아제 컨쥬게이트 및 인히비터 |
CN104736569A (zh) | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
EP2920183B1 (fr) * | 2012-11-14 | 2017-03-08 | Glaxosmithkline LLC | Thiéno[3,2-c]pyridin-4(5h)-ones utiles comme inhibiteurs de bet |
SI3290407T1 (sl) * | 2013-10-18 | 2020-07-31 | Celgene Quanticel Research, Inc | Inhibitorji bromodomene |
AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US10633386B2 (en) * | 2016-04-12 | 2020-04-28 | The Regents Of The University Of Michigan | BET protein degraders |
-
2017
- 2017-06-23 CA CA3025806A patent/CA3025806C/fr active Active
- 2017-06-23 AU AU2017281903A patent/AU2017281903B2/en not_active Ceased
- 2017-06-23 WO PCT/US2017/039004 patent/WO2017223452A1/fr unknown
- 2017-06-23 US US16/312,586 patent/US11285218B2/en active Active
- 2017-06-23 EP EP17816295.4A patent/EP3474900A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US11285218B2 (en) | 2022-03-29 |
CA3025806C (fr) | 2023-04-04 |
EP3474900A4 (fr) | 2020-03-11 |
CA3025806A1 (fr) | 2017-12-28 |
AU2017281903A1 (en) | 2018-12-13 |
US20190247509A1 (en) | 2019-08-15 |
AU2017281903B2 (en) | 2020-12-24 |
WO2017223452A1 (fr) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017281903B2 (en) | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | |
WO2017117474A1 (fr) | Composés bifonctionnels destinés à la dégradation d'her3 et procédés d'utilisation | |
US20200216454A1 (en) | Bifunctional molecules for her3 degradation and methods of use | |
RU2671494C2 (ru) | Некоторые ингибиторы протеинкиназы | |
CA3140972A1 (fr) | Combinaisons comprenant du benzodioxol en tant qu'agonistes de glp-1r destinees a etre utilisees dans le traitement de la nash/nafld et de maladies associees | |
JP2019163324A (ja) | Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置 | |
CN114980976A (zh) | 共价ras抑制剂及其用途 | |
EP3365340A1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
CA3110502A1 (fr) | Composes pyrazolo[3,4-b]pyridine utilises en tant qu'inhibiteurs de kinases tam et met | |
US20230242505A1 (en) | Process, compositions, and crystalline forms of substituted pyridinone-pyridinyl compounds | |
US10179771B2 (en) | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
WO2020191022A1 (fr) | Inhibition de la peptidase 9x spécifique de l'ubiquitine | |
CA3087797A1 (fr) | Combinaisons pharmaceutiques d'inhibiteurs d'egfr et leurs procedes d'utilisation | |
CA3220274A1 (fr) | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr | |
EP3852792A1 (fr) | Inhibition de la peptidase 9x spécifique de l'ubiquitine | |
JP2023516645A (ja) | Tead阻害剤としてのヘテロ二官能性分子 | |
TW202340209A (zh) | 用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物 | |
CN108137556B (zh) | 1,4-二羰基-哌啶基衍生物 | |
TWI768781B (zh) | 轉化生長因子-β受體抑制劑 | |
ES2549443T3 (es) | Pirimido[1,2-b]indazoles sustituidos y su uso como moduladores de la ruta de PI3K/AKT | |
EP3755338A1 (fr) | Combinaisons pharmaceutiques d'inhibiteurs d'egfr et leurs méthodes d'utilisation | |
AU2019225806A1 (en) | Inhibitors of EGFR and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190122 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0047500000 Ipc: A61K0047550000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200210 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/50 20170101ALI20200204BHEP Ipc: A61K 47/55 20170101AFI20200204BHEP Ipc: A61P 35/00 20060101ALI20200204BHEP Ipc: C07D 495/04 20060101ALI20200204BHEP Ipc: C07D 401/14 20060101ALI20200204BHEP Ipc: C07D 471/04 20060101ALI20200204BHEP Ipc: A61K 31/4365 20060101ALI20200204BHEP Ipc: A61K 31/4035 20060101ALI20200204BHEP Ipc: A61K 47/54 20170101ALI20200204BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40008079 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221129 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20240103 |